NIH SIREN Emergency Trials Network

POST-ICECAP

STUDY PROTOCOL

Patterns **O**f **S**urvivors' Recovery **T**rajectories in the **ICECAP** trial (**POST-ICECAP**)

POST-ICECAP is an ancillary study to the NINDS/NHLBI funded 'Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients' trial, conducted within the NIH Strategies to Innovate Emergency Care Clinical Trials Network. POST-ICECAP will describe the extent of improvement or deterioration in functional, cognitive, and health-related quality of life outcomes within 12 months after an out of hospital cardiac arrest (OHCA). It will estimate the prospective associations of clinical interventions, rehabilitation, and social determinants with those dimensions of recovery in a large, well-characterized, racially/ethnically diverse, US-representative cohort of OHCA patients.

Study Principal Investigators:
Sachin Agarwal (Contact), Clifton W. Callaway

Study Biostatistician:
Joseph E. Schwartz

Supported by grants:
R01NS127959-01A1 from the National Institute of Neurological Disorders and Stroke (NINDS), The National Heart, Lung, and Blood Institute (NHLBI)

Protocol Version 2

Protocol Signature Page

I have reviewed and approved this protocol. My signature assures that this study will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality.

16-May-2025

Sponsor's Signature | Date of Signature (DD MMM YYYY)

I have read this protocol and agree that it contains all the necessary details for carrying out the study as described. I will conduct this protocol as outlined herein, including all statements regarding confidentiality. I will make a reasonable effort to complete the study within the time designated. I will provide copies of the protocol and access to all information furnished by the Sponsor to study personnel under my supervision. I will discuss this material with them to ensure that they are fully informed about the drug and the study. I understand that the study may be terminated or enrollment suspended at any time by the Sponsor, with or

I agree to conduct this study in full accordance with all applicable regulations and Good Clinical Practices (GCP).

Investigator's Signature | Date of Signature (DD MMM YYYY)

Contact Information

Sachin Agarwal, MD, MPH
Scientific lead, Co-Principal Investigator
Sa2512@columbia.edu

Clifton W. Callaway, MD, PhD
Logistical Lead, Co-Principal Investigator
callawaycw@upmc.edu

Sharon Yeatts, PhD
Data Coordinating Center, Principal Investigator
yeatts@musc.edu

Will Meurer, MD, MS
Clinical Coordinating Center, Principal Investigator
wmeurer@umich.edu

SIREN Emergency Clinical Trials Network
Clinical Coordinating Center
University of Michigan
24 Frank Lloyd Wright Dr.
Suite H3100
Ann Arbor, MI 48106
734-232-2142

Table of Abbreviations

CCC	Clinical Coordinating Center
co-I	Co-Investigator
co-PI	Co-Principal Investigator
CRF	Case Report Form
DCC	Data Coordinating Center
DCR	Data Clarification Request
DCU	Data Coordination Unit
DoC	Disorders of Consciousness
DSM-5	Diagnostic and statistical manual of mental disorders
ED	Emergency Department
EMS	Emergency Medical Services
FDA	Food and Drug Administration
HRQoL	Health Related Quality of Life
ICU	Intensive Care Unit
IRB	Institutional Review Board
LAR	Legally Authorized Representative
mRS	Modified Rankin Scale
MUSC	Medical University of South Carolina
NIH	National Institutes of Health
OHCA	Out-of-Hospital Cardiac Arrest
PI	Principal Investigator
PICS	Post-Intensive Care Syndrome
PTSD	Post-Traumatic Stress Disorder
ROC	Resuscitation Outcomes Consortium
SDOH	Social Determinants of Health
SES	Socio-economic Status
SIREN	Strategies to Innovate Emergency Care Clinical Trials Network
SSL	Secure Socket Layer
SOP	Standard Operating Procedures
WLST	Withdrawal of Life Sustaining Treatments

TABLE OF CONTENTS

BRIEF SYNOPSIS

Title	**P**atterns **o**f **S**urvivors' Recovery **T**rajectories in the **ICECAP** Trial (**POST-ICECAP**)
Methodology	Prospective cohort study ancillary to an ongoing multi-center, randomized trial
Funding Agencies	R01NS127959-01A1 NINDS/NHLBI
Study Duration	June 2023 to June 2028
Study Center(s)	SIREN Trial Network
Objectives	**Primary**: Describe between-patient variability in the improvement of functional, cognitive, and quality of life outcomes from 3 to 12 months after OHCA. **Secondary**: 1. Determine whether changes are associated with illness severity scores and critical care interventions performed during the acute care stay. 2. Determine whether receipt of acute inpatient rehabilitation versus outpatient therapy/no therapy/skilled nursing facility within 1 month of hospital discharge is associated with greater improvement in recovery outcomes from 3 to 12 months. 3. Determine whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such differences.
Endpoints	**Primary:** Performance-based measures of functional outcome (Modified Rankin). **Secondary**: Performance-based measures of cognitive function: 1. NIH toolbox Age-corrected Standard Score for 3 and 12 months in-person visits; Brief Test of Adult Cognition by Telephone (BTACT) total score at 1-,3-, 6-, 9- and 12-month phone visits. 2. Patient-reported Health-Related Quality of Life as measured on NIH Neuro-QoL at 3 and 12 months in-person visits
Participants	1000 OHCA survivors
Study Visits	Telephone Interview (or in-person): 1, 6, and 9 months after OHCA In-person Interview: 3 and 12 months after OHCA
Study Measures	**Intake Questionnaire:** ● NIH Socio-demographics assessments ● Experiences of Discrimination Scale ● Premorbid modified Rankin Scale ● Pre-morbid 4-item PTSD scale **Every Visit:**

	● modified Rankin Scale (and Disability Rating Scale only for patients who are unable to follow commands) ● Brief Test of Adult Cognition by Telephone ● Generalized Anxiety Disorder-2 ● Patient Health Questionnaire - 8 ● The PTSD Checklist for DSM-5 ● Neuro-QoL Item Bank v1.0 – Upper and Lower Extremity Function ● Australian Modified Lawton-Brody Instrumental Activities of Daily Living ● Neuro-QoL Item Bank v1.0 – Fatigue ● Kansas City Cardiomyopathy Questionnaire (KCCQ-12) ● ENRICHD Social Support Instrument ● Health care and rehabilitation service utilization **In-Person Only (3 and 12 months):** ● NIH Toolbox - neuropsychological tests ● NIH Neuro-QoL
Duration of study	12 months after OHCA
Statistical Methodology	Primary analyses will be performed on patients w/ mRS<5 (awake patients; anticipated n=750) at 1 month, but descriptive/exploratory analyses will be performed on those w / 1-month mRS=5 (n=250). We will analyze these two strata separately as patients with disorders of consciousness will have qualitatively different recovery and systematically different exposures to modifiers like rehabilitation (ineligible for inpatient acute rehabilitation). Each Aim focuses on the change in function, cognition, and HRQoL from 3 to 12 months. To test the hypotheses for our Aim 1, initial illness severity (total OHCA score as primary predictor, Pittsburgh Cardiac Arrest Category score as secondary predictor), early coronary angiography, and duration of hypothermia are associated with a change from 3 to 12 months in mRS (primary outcome), NIH-Toolbox and Neuro-QoL (secondary outcomes). The same analytic approach will be used to address Aims 2 and 3, with the primary predictors being the receipt of inpatient acute rehabilitation (vs. outpatient rehabilitation/no rehabilitation/discharge to a skilled nursing facility; Aim 2) or race/ethnicity (non-Hispanic Black race, Hispanic/Latinx ethnicity vs non-Black/non-Hispanic patients [reference group]; Aim 3).

SYNOPSIS

Many patients now survive out-of-hospital cardiac arrest (OHCA); however, gaps in knowledge about long-term outcomes result in a fragmented and underdeveloped continuum of care to achieve recovery. Recovery is defined as significant improvement in functional and cognitive outcomes and health-related quality of life

(HRQoL). OHCA survivors with favorable recovery patterns may potentially go back to work and/or social roles. Prior studies assessing recovery domains after OHCA are small, limited to single centers and short-term outcomes, i.e., 1-3 months. The ability to identify individual patient patterns of recovery over longer-term, and to predict who will be likely to need more intensive support after discharge, would allow interventions to be targeted more efficiently. It is also crucial that we offer patients and their families the best information available about a patient's prospects for continued recovery even in the absence of modifiable intervention targets. This study will be among the first to focus on a new equitable science of OHCA survivorship itself, seeking empirically derived targets for preserving or restoring recovery.

To accomplish these goals, we propose "Patterns Of Survivors' Recovery Trajectories in the ICECAP trial (POST-ICECAP)", an ancillary study to the NHLBI and NINDS-funded ICECAP trial, conducted within the NIH-funded Strategies to Innovate Emergency Care Clinical Trials Network (SIREN). The goal of POST-ICECAP is to describe recovery in a large, well-characterized, racially/ethnically diverse, representative cohort of US OHCA patients. We will enroll 1,000 patients who were treated with targeted temperature management (TTM) and survived to 1 month at multiple sites, many of whom are actively screening and enrolling in ICECAP. The ICECAP trial includes a telephone follow-up visit at 1 month and an in-person visit at 3 months. This overlapping study will add two telephone/videoconferencing visits at 6 and 9 months and an in-person visit at 12 months after OHCA.

For Aim 1, we will describe between-patient variability in recovery (i.e., improvement in functional, cognitive, and HRQoL outcomes) from 3 to 12 months after OHCA and test whether changes are associated with illness severity scores and critical care interventions performed during the initial hospitalization. Aim 2 will test whether receipt of acute inpatient rehabilitation (vs outpatient therapy/no therapy/skilled nursing facility) within 1 month of hospital discharge is associated with greater improvement in recovery outcomes from 3 to 12 months. Finally, in Aim 3, we will test whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such differences.

1. STUDY OBJECTIVES

Primary:

Describe between-patient variability in the improvement of functional, cognitive, and HRQoL outcomes from 3 to 12 months after OHCA.

Secondary:

1. Determine whether changes are associated with illness severity scores and critical care interventions performed during the acute care stay.
2. Determine whether receipt of acute inpatient rehabilitation versus outpatient therapy/no therapy/skilled nursing facility within 1 month of hospital discharge is associated with greater improvement in recovery outcomes from 3 to 12 months.
3. Determine whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in

recovery outcomes between 3 and 12 months and explore mechanisms for such differences.

2. BACKGROUND

2.1 Burden of Cardiac Arrest Survivorship

In the US, nearly 1,000 adults experience a sudden OHCA each day.[1,2] An electrical malfunction is triggered by a disruption of the heart's rhythm, and the heart ceases to pump blood to the brain, lungs, and other organs.[3,4] Coronary artery or other heart disease is the most common etiology.[3] Over 15% (60,000/year) of all OHCA patients survive to hospital discharge,[5,6] thanks to effective public health campaigns for cardiopulmonary resuscitation,[2,7] defibrillators,[8-10] and advances in bundled post-arrest intensive care,[11-16] based on the American Heart Association's original five links of the *'Chain of Survival'* **(Figure 1).** Now that more patients are surviving OHCA, we must identify strategies to ensure that patients live long, healthy, disability-free lives. Indeed, national[5,17] and international[18] scientific bodies recently issued a scientific statement declaring that OHCA survivors have "unique and complex needs that are inadequately addressed by current treatment recommendations".[5] POST-ICECAP will address major knowledge gaps surrounding the key 'sixth link' in the Chain of Survival: 'survivorship' or the recovery phase.



Figure 1. The Sixth Link of Chain of Survival: From Survival to Recovery

2.2 The conceptual framework for recovery after OHCA is grounded in the World Health Organization's International Classification of Functioning Disability and Health (WHO-ICF).



Figure 2. Proposed OHCA Recovery Framework, an adaptation of WHO-ICF model,[48] demonstrating 1) the three primary domains of recovery (impairments, activity or functional limitations, and HRQoL/participation restrictions), 2) Influence of factors related to clinical course, individual and structural components of Social Determinants of Health (SDOH), on functional and cognitive recovery & HRQoL.

OHCA is a particularly challenging condition to manage clinically, due to the heterogeneous nature of the injury. OHCA survivors with apparently similar brain injury profiles can experience very different functional, cognitive, and HRQoL outcomes.[19-24] This variability may be partly attributable to differences in personal biology, including a complex interplay between premorbid and injury-induced pathophysiology.[12,25-29] However, our prior research suggests that recovery is determined in part by potentially modifiable factors, including aspects of critical care,[12,15,30-34] intensity of rehabilitation services after hospital discharge,[19,35] and the physical and social environments,[35-39] in which recovery takes place. In **Figure 2** we present a biopsychosocial framework that encompasses multiple domains of recovery related to impairments in structure and function, activity limitations, participation restrictions, and poor HRQoL and that contextualizes the important predictors affecting variability in recovery. Identifying factors that are associated with patient heterogeneity in recovery is the critical first step toward evidence-based personalized recovery plans and treatments.[26,40-42]

2.3 Understanding why recovery continues for many months in some patients, while others plateau or regress, will inform future OHCA intervention trial design, assist patients and families in planning transitions of care, and allow for personalized interventions and plans of care. Currently, referral to acute rehabilitation after hospital discharge is not routine, in part because the clinical evidence is weak or absent about whether an OHCA patient should expect continued recovery, or if further rehabilitation efforts are futile.

2.4 Rationale

We propose the first national study of factors associated with recovery from 3-12 months post-resuscitation in patients who experienced an OHCA. Patients are now almost 3 times more likely to survive to hospital discharge after OHCA (~60,000 survivors per year) compared to 10 years ago.[1,2,5,43] However, over 50% of survivors have a persistent neurological impairment, ranging from mild cognitive deficits to disorders of consciousness or coma,[5,6,12,29,41,44] due to hypoxic-ischemic injury to the brain. *Recovery* is defined as significant improvement in functional and cognitive outcomes, and health-related quality of life (HRQoL). Patients with good recovery can return to employment and/or social roles.[13,19,20,22,25,41,45-57]

The paucity of data about long-term recovery after acute hospitalization is a major reason that there are no clear guidelines for after-hospital care or intense rehabilitation for OHCA. Most data about functional or cognitive recovery focus on short-term outcomes, i.e., 1-3 months after OHCA.[5,6,28,58] In a recent, single-center pilot study, we found substantial variability in recovery after 3 months,[19,35] suggesting that 3-month recovery status does not dictate recovery status at 12 months.

Currently, clinical practice and rehabilitation efforts are optimized for recovery outcomes assessed at 1-3 months after OHCA. Patients and families don't know whether to expect further improvement after 3 months or if there is a ceiling beyond which no further recovery is likely. Together with ICECAP, this proposed study will provide the best evidence to date about patients' longer-term recovery prospects after OHCA. It may generate evidence for systematic referral to acute inpatient rehabilitation for most patients and the characteristics of those patients most likely to benefit from such rehabilitation. Our study may also point to racial and/or ethnic differences in recovery, as well as intervention targets to reduce such differences. As such, this study represents a critical step toward understanding and supporting widespread, equitable recovery after OHCA.

2.5 Supporting Data

In preparation for this proposal, we analyzed data from a prospective, observational pilot study[35,53,59] of 261 diverse (24% Hispanic/Latinx and 19% Black) adult (mean 56±16 years) OHCA survivors (40% women) with the ability to follow commands and participate in an interview at 1-month after OHCA between 2/1/2016 and 1/31/2020. We measured participants' functional outcomes (modified Rankin Scores; mRS) and cognitive impairment



Figure 3. Functional status (mRS) at 1 and 12 months after OHCA. Good Recovery Pattern is maintenance of mRS 0-2 or improvement, and Poor Recovery Pattern is persistent mRS 3-5, worsening mRS or death.

[Repeatable Battery for Neuropsychological Status (RBANS)[50,60]] at 1, 3, and 12 months post-OHCA. We also examined biopsychosocial factors including **demographics** (age, sex), **social determinants of health** including self-reported race/ethnicity, caregiver status, individual-level socioeconomic status (SES): insurance, education level, income, occupation, structural-level SES: Area deprivation index[61-63]), **clinical factors** (comorbidities, components of OHCA severity score[64,65], in-hospital factors, hospital length of stay), and **discharge disposition** (inpatient acute rehabilitation, outpatient rehabilitation, no rehabilitation, skilled nursing facility).

2.5.1 Functional Recovery Variation from 1 to 12 Months. We confirmed our prior observations[19] that in nearly half of the participants, there are clinically important differences between long-term (12 months) and early (1 month) functional outcomes (**Figure 3**). Most (63%, n=127/201) maintained good functional status or improved, but over one-third (37%, n=74/201) of patients had a poor functional recovery pattern, defined as death, or persistent unfavorable functional outcomes, i.e., mRS between 3-5, or any worsening of mRS from 1 to 12 months.[35]

2.5.2 Similar Variation in Cognitive Recovery Patterns from 1 to 12 months. Among the 64% (n=117/182) with cognitive impairment at 1 month (≥80 on RBANS, a threshold used for moderate traumatic brain injury), 30% (n=55/117) had persistent cognitive impairment at 12 months (poor recovery pattern), while 34% (n=62/117) showed improvement (good recovery pattern).[36]

2.5.3 Variation from 3-12 Months. Because the OHCA recovery studies with the longest follow-up tend to end at 3 months, we estimated variation in further recovery from 3-12 months. We found that one-third of patients (n= 66) had a change in their functional outcome between 3 and 12 months (**Figure 4**), including those with a favorable status at 1 month (n=14, 31%; Trajectories 2 & 3) and those with an unfavorable status at 1 month (n=52, 39%; Trajectories 6 & 7). POST-ICECAP will explore what factors influence whether a patient experiences a good or poor recovery pattern from 3 to 12 months after OHCA.



Figure 4. Recovery Patterns of Patients with **(A)** Favorable functional outcomes (mRS 0-2), **(B)** Unfavorable functional outcomes (mRS 3-5) at 1-month after OHCA.

Selection of performance-based and patient-reported outcomes of Recovery in POST-ICECAP.

2.5.4 Functional outcome (Performance-based Outcome, Primary Study Outcome) includes difficulties with or dependence on others for

everyday activities and is a critical patient-centered outcome.[5,25,58] Almost half of OHCA survivors have persistently poor functional outcomes.[6,19,20,22,66,67] This poor functional recovery leads to low participation in social and leisure activities, inability to return to work, and poor family relationships.[57,66,68,69] POST-ICECAP will evaluate a well-established measure of functional outcome, the Modified Rankin Scale,[58,70-72] to yield a detailed picture of functional recovery over 12 months after OHCA.

2.5.5 Cognitive Function (Performance-based Outcome, Secondary Study Outcome). Mild to severe cognitive impairment occurs in 25–60% of OHCA survivors[20,48,50,55,66,73,74] and persists months to years after hospital discharge.[6,28,75,76] In our pilot cohort, we found a high prevalence of cognitive impairment at 1 and 12 months, with the most prominent impairments in attention, immediate memory, and delayed memory **(Figure 5)**.[20] OHCA survivors with cognitive dysfunction generally have worse HRQoL and social functioning, a lower likelihood of returning to work, and more psychological distress than those without cognitive dysfunction.[6,54,55,57,77] POST-ICECAP will collect serial measurements to reliably quantify individual cognitive outcomes using the global Age-adjusted standardized cognition score (primary cognitive outcome) and sub-types summary scores derived from a battery of neuropsychological tests (NIH toolbox) and a validated brief telephone-based test.

Figure 5. High prevalence of cognitive impairments across all sub-types at 1 and 12 months, using the threshold for moderate traumatic brain injury.

2.5.6 Health-related Quality of Life and Societal Participation (Patient-reported, Secondary Outcome). Quality of life is the most important consideration of OHCA survivors.[5,23,58,78,79] HRQoL estimates inform health economic assessments of intervention cost-effectiveness, and therefore identifying factors that are associated with HRQoL is key for identifying potential intervention targets and evaluating treatments. Perhaps because clinical expectations were so low for decades, current practice yields HRQoL scores in OHCA patients that are 0.5-1 SD below norms for their age.[69] Subgroup analyses show that younger patients (18-44 years) have 0.4 SD lower HRQoL than older patients, and women have significantly lower scores than men (0.35 SD lower).[69] However, we have shown that societal participation improves over 12 months and is strongly correlated with functional recovery.[22] POST-ICECAP will estimate HRQoL and societal participation and identify changes in overall and physical, social, emotional, and cognitive health sub-scales between 3 and 12 months after OHCA. The primary HRQoL outcome will be the total summary score on NIH Neuro-QoL.

2.5.7 OHCA survivors with disorders of consciousness (DoC) are a critical but neglected subgroup**.** We have documented that withdrawal of life-sustaining treatments (WLST) for patients with DoC (i.e., unresponsive and not following simple commands) within a few days after OHCA is widespread[27,80] and estimated to be responsible for as many as 20,000 additional OHCA-related deaths per year.[81] This is due to limited data on

long-term recovery from DoC and a belief among clinicians that these patients will show no long-term improvement. The *2018 American Academy of Neurology practice guideline update* makes clear that recovery from DoC after acute brain injury can occur later than previously believed, with meaningful functional improvement in a substantial minority.[82] We have recently shown that up to 20% (190/975) of patients discharged from the hospital after OHCA have a severe functional disability and, of those, 23% do not follow commands at discharge.[83] We and others have reported recovery of consciousness in up to 20% of OHCA survivors discharged to in-person acute rehabilitation while still unconscious.[84-86] Nearly half (41%) of those who regained consciousness after discharge also experienced meaningful functional improvements that were not yet apparent at 3 months. The proposed study will aid in the identification of those who may recover.[28] POST-ICECAP will be the largest study to systematically examine the natural clinical course (over 12 months) of patients who remain unresponsive before hospital discharge.

2.5.8 Selection of factors that may influence recovery in POST-ICECAP.

To improve clinical care, we seek to identify potential targets for interventions that are associated with improved outcomes after OHCA. In POST-ICECAP we will investigate the prospective associations of clinical factors and interventions in the acute care setting, post-discharge rehabilitation services, and social determinants of health with continued recovery or regression on functional, cognitive, and HRQoL outcomes.

2.5.8.1 <u>OHCA severity of brain injury set the stage for variability in recovery</u>: Whether long-term outcomes are associated with OHCA illness severity scores that predict survival and functional status at hospital discharge is a knowledge gap.[41,42,87-89] We derived and validated one score, the Pittsburgh Cardiac Arrest Category (PCAC),[12,31,90,91] based on the motor and brainstem subscales of the Full Outline of UnResponsiveness (FOUR) scores[92-94] and cardiovascular and respiratory subscales of the Sequential Organ Failure Assessment (SOFA) score.[95,96] POST-ICECAP will leverage the comprehensive and systematically collected physiological and biomedical data to examine how these physiological assessments are associated with recovery from 3-12 months.



Figure 6. Forest plot showing a beneficial effect of inpatient rehabilitation on functional Independence Measure (FIM) score between admission and discharge.

2.5.8.2 <u>Clinical interventions, including ICECAP randomized duration of hypothermia, may influence recovery.</u> Hypothermia is a guideline-recommended treatment for comatose survivors of OHCA,[1,97] but whether the duration of hypothermia influences long-term recovery patterns is unknown. Human data about prolonged duration of hypothermia after OHCA are lacking,[98] but mechanistic and preclinical outcome data suggest potential benefits.[99-101] Hypothermia is delivered in conjunction with many other critical care interventions, including specific blood pressure goals,[102] mechanical ventilators settings[103], renal replacement therapy,[33] sedation and

neuromuscular blockade regimens,[104] and treatments (e.g. early coronary angiography).[105-109] While the ICECAP trial will examine associations between the duration of hypothermia and 3-month outcomes, POST-ICECAP will test whether the duration of hypothermia is associated with continued recovery from 3-12 months. For primary analyses, we will also test if angiography performed within 24 hours is associated with greater improvement in recovery.



Figure 7. Proportion of patients with poor functional outcome at 1 and 12 months, by discharge disposition

2.5.8.3 Inpatient acute rehabilitation may improve recovery. Currently, there are no guidelines or recommendations for neurorehabilitation for OHCA survivors in the US.[5] Whether inpatient acute rehabilitation is commonly provided to OHCA survivors is a major knowledge gap. Outside of reports[19,35,110] from a few tertiary care centers, including our own, the proportion of OHCA survivors who receive physical, occupational, speech, or physiatry evaluations and disposition to continue rehabilitation after hospital discharge is not known. A recent systematic review found patients improved between admission and discharge from inpatient acute rehabilitation after CA (medium-large effect size) **(Figure 6)**.[111] In our data, patients who received inpatient acute rehabilitation (vs other discharge dispositions) after acute care hospital stay were significantly more likely to progress from poor functional outcomes to good functional outcomes between 1 and 12 months (**Figure 7**). In models adjusted for demographics, clinical characteristics, and social determinants of health, patients who received acute inpatient rehabilitation were 3 times more likely to achieve a good functional recovery pattern.[35]

In two geographically distinct cohorts, we have shown that a substantial proportion of patients with poor functional status at hospital discharge return to home, either with no rehabilitation or with home healthcare.[110] There are significant sex-based differences in receipt of inpatient acute rehabilitation.[112] These patients may be an unrecognized “at-risk” group, potentially with unfavorable social determinants, who experience worsening or flat recovery patterns from discharge to 12 months. POST-ICECAP will be the first prospective multicenter study to **(a)** describe with a high degree of granularity the in-hospital rehabilitation evaluations/services received before discharge and the rehabilitation services offered and received after hospital discharge, **b)** examine what factors, either clinical (e.g., medical complexity, the severity of impairments at discharge) or sociodemographic (e.g., insurance, presence of a caregiver, sex, race/ethnicity), are associated with these decisions about alternative discharge dispositions, and **(c)** test whether attending an inpatient acute rehabilitation within 1 month after surviving OHCA is associated with recovery.

2.5.8.4 Social determinants of health (SDOH) influence recovery after OHCA**.** Prior research identified racial and ethnic differences in OHCA incidence and mortality.[113-122] There is a gap in our knowledge about racial/ethnic differences in longer-term recovery after OHCA. Understanding which SDOH contributes to racial and ethnic differences after OHCA is critical for reducing those differences. Limited data on other cardiac and critical care illnesses indicate that historically marginalized groups are at higher risk of poor functional outcomes with worse HRQoL, impaired societal participation, and perhaps because of differences in follow-up care or employment security, compared with White patients.[123-128] No national data exist for OHCA survivors.



Figure 8. Proportion of patients with poor functional outcomes at 1 and 12 months by Race/Ethnicity

In our study of 201 patients discharged from the hospital after OHCA, multiple social factors were associated with improvement or worsening between 1 and 12 months. For example, the proportion of non-Hispanic Whites who had poor function (mRS>2) decreased 50% from 1 to 12 months, but only 10% of Blacks and 8% of Hispanics exhibited similar improvement (**Figure 8**). In multivariable models, Black race and Hispanic ethnicity, poor insurance, non-working status, absence of a caregiver/spouse, and high area deprivation index as an indicator of neighborhood SES, were independently associated with a poor cognitive recovery pattern from 1-12 months after OHCA. The differencies we found are clearly multifactorial, with self-reported race aligning with other individual-, structural-, and hospital-level factors at several points in the course of recovery after OHCA. Structural racism and race-based stressors may also contribute to these differences. POST-ICECAP will deepen our understanding of where differences exist in OHCA recovery and may point to targets for interventions to reduce health differencess in OHCA.

2.5.8.5 Post-Intensive Care Syndrome (PICS) and Psychological Distress in OHCA survivorship. Our pilot data suggest that many patients continue to improve on functional, cognitive, and psychological or HRQoL measures after 3 months, but some deteriorate on 1 or more dimensions. One of the ways the field describes new or worsening deficits is through the concept of PICS. Our serial measurements include the PICS components (function, cognition, and psychological distress), and we will be the first national study to document the prevalence and predictors of PICS or recovery from 3 to 12 months after OHCA. POST-ICECAP will be the most comprehensive study of the psychological dimension of OHCA recovery ever conducted.

OHCA occurs suddenly and often without warning in apparently healthy individuals, young or old, of any sex.[129] Survivors experience 2-3 weeks of critical illness.[53] The psychological experience of OHCA is traumatic and life-altering.[78,79] Nearly 1/3 of OHCA patients screen positive for posttraumatic stress disorder (PTSD) at 1 and 12 months after OHCA,[24,53,130] a rate that is 2.5 to 3 times greater than other acute cardiovascular conditions (32% for OHCA vs 11-15% for acute coronary syndrome or stroke).[131-135] Similarly, depression and generalized anxiety are very common among OHCA survivors (14%-45%).[50-52,56,59,136,137] We have shown that psychological distress coexists with cognitive and functional impairments at 1 and 12 months after OHCA.[59] Only 10% of survivors had no measurable psychological distress or functional or cognitive impairments at 1 month (**Figure 9**).



Figure 9. The prevalence of post-intensive care syndrome components, and co-occurrence of psychological distress with functional and cognitive deficits at **(A) 1 month, (B) 12 months** after OHCA. *% denotes proportion of patients.*

In summary: POST-ICECAP will address a critical knowledge gap by describing long-term recovery after OHCA in a national cohort of US patients, including unresponsive DoC patients, identifying between-patient variability in recovery after 3 months, and estimating how acute care factors, receipt of inpatient acute rehabilitation, and race/ethnicity (likely through SDOH) relate to recovery in OHCA survivors (**Figure 10).**

Figure 10. Conceptual Figure

3. STUDY DESIGN

3.1 Study Design

POST-ICECAP is a prospective cohort study of patients who survive to 1 month after OHCA. Participants will complete two in-person visits at 3 and 12 months (primary outcomes assessment), and three telephone visits at 1, 6, and 9 months post-OHCA. We will administer validated measures of functional outcomes, cognitive performance, HRQoL, rehabilitation details, and a biopsychosocial questionnaire. See **Figure 11** for study visits.



Figure 11. Study Schema showing the frequency of POST-ICECAP visits.

3.2 Clinical Sites

Hub and spoke hospitals from the SIREN network who are using targeted temperature management, whether or not they are participating in ICECAP, will be eligible for participation in POST-ICECAP. At least50 hospitals are anticipated to enroll an average of 5 subjects per year. The enrollment period is anticipated to be 4 years (estimated accrual rate of 21 subjects per month).

4. SELECTION AND ENROLLMENT OF SUBJECTS

4.1 Study Population

Study population will comprise adults, treated with targeted temperature management, including those enrolled in or screened for the ICECAP trial, who survived to 1 month after an OHCA. Detailed inclusion/exclusion criteria are listed in **Table 1**. Enrolling a cohort of OHCA survivors by using the geographically widespread SIREN sites is a major strength of our protocol.

Table 1. Inclusion Criteria	**Exclusion Criteria**
● Age ≥ 18 years ● Coma after resuscitation from OHCA ● ● Received targeted temperature management ● Participant survived to 1 month ● Signed ICF by a patient or an authorized representative	● Neither English nor Spanish speaking ● Terminal non-cardiovascular illness (life expectancy <1 year) ● Hospice as disposition ● Severe mental illness requiring urgent psychiatric care ● Pre-existing conditions that could confound outcome determination e.g., dementia. ● Known inability to follow up (e.g., no reliable phone or internet access)

4.2 Informed Consent and Enrollment

At all ICECAP sites, screen failure data is entered on all patients with an emergency department diagnosis

consistent with cardiac arrest (ICD-10 code of I-46, I-49.01, I47.2, R96, R98, R99, or equivalent codes in another diagnostic system) that are treated in the ED but not enrolled. Research teams will evaluate eligibility of patients based on criteria listed in **Table 1** and invite these patients or their proxies to participate in their preferred language of English or Spanish. Screen failures for ICECAP might be approached in the hospital after an introduction by the treating team or even after hospital discharge before the first POST-ICECAP evaluation (1-month post-OHCA). Research teams are already involved with subjects enrolled in ICECAP and will approach for POST-ICECAP consent during the hospitalization as soon as it has been determined that the patient is likely to survive hospitalization (e.g., when being released from the ICU) or any time before 1 month after OHCA. Of note, proxies may consent for patients who do not yet have the capacity for themselves (e.g., those with disorders of consciousness and unable to follow commands). Participants are considered to be enrolled in POST-ICECAP if (1) they (or their proxy) have provided informed consent and (2) they have survived beyond 1 month after OHCA.

At hospitals who are not enrolling in ICECAP, research teams will screen and approach patients using similar methods.

5. STUDY ASSESSMENTS

5.1 Measurement timepoints

Once the consent is obtained, participants or surrogates will engage in an intake-questionnaire capturing socio-demographics information, their prior experiences of discrimination due to race/ethnicity/color, functional status before OHCA and any pre-existing post-traumatic stress symptoms.

To minimize participant burden, the data collection schedule differs for ICECAP and non-ICECAP participants. For subjects enrolled in ICECAP, POST-ICECAP will not repeat measures collected as part of the overlapping 1 and 3 month visit with the ICECAP trial. Specifically, POST-ICECAP will capture the mRS at 1 and 3 months, neuropsychological testing, and HRQoL assessments for non-ICECAP participants but not for subjects enrolled in ICECAP. Beyond 3 months post-arrest, the collection schedule is the same for both ICECAP and non-ICECAP participants. The study team will contact participants via telephone at 6 and 9 months after OHCA and plan an in-person assessment at 12 months (POST-ICECAP primary outcome assessment) (**Figure 11**). At each of the 5 study visits, participants will complete measures of functional outcome, cognitive function, and psychological distress. They will provide details on health care and rehabilitation utilization, and complete assessments on disability, fatigue, social support and day-to-day limitations due to cardiac function. At the in-person 3-month and 12-month visits, participants will also complete an in-person neuropsychological test and a computerized adaptive testing assessment of HRQoL. For patients with DoC at any of the follow-up visits, only the functional outcomes will be collected from a telephone interview with a primary caregiver.

5.2 Efficiencies provided to POST-ICECAP by ICECAP trial

5.2.1 Screening and access to patients. The ICECAP research teams have surveillance strategies in place to screen all OHCA patients at participating hospitals. Research teams track ICECAP randomized patients through 3 months and ICECAP screen failures through hospital discharge. Thus, POST-ICECAP can use research teams

that already have contact and entrée to approach all the OHCA patients admitted at their hospitals and do not need to create or directly support the screening process. At hospitals who are not enrolling in ICECAP, research teams will screen and approach patients using similar methods.

5.2.2 Baseline and clinical care data. Research teams for ICECAP prospectively collect, audit, and monitor detailed information about the patient comorbidities, OHCA-related factors, acute hospital events, and procedures performed during hospitalization. POST-ICECAP can use the data already collected for subjects enrolled in ICECAP, saving hundreds of hours of research staff time compared to collecting these de novo. Note: POST-ICECAP will still capture these measures for non-ICECAP participants.

5.2.3 Duration of hypothermia. In the parent ICECAP trial, adaptive randomization is used to assign patients to one of ten possible durations of hypothermia (6, 12, 18, 24, 30, 36, 42, 48, 60, or 72 hours). In the subset of patients who were randomized in ICECAP and then enrolled in POST-ICECAP, we can test whether hypothermia duration influences recovery trajectories beyond the 3-month ICECAP primary outcome.

6. OUTCOMES

6.1 Primary Efficacy Outcome

The primary outcome measure will be the mRS at 12 months after OHCA. The mRS will be analyzed as a weighted score incorporating both the proportion of subjects achieving a good neurological outcome and degree of residual functional impairment among those with good neurological outcomes. The mRS will be determined by a site investigator or research staff certified by the CCC in the performance of the scale.

6.2 Secondary Efficacy Measures - Patient Reported Outcomes

Neuro-QoL is a set of self-report measures that assesses the HRQoL of adults with neurological disorders. Neuro-QoL consists of item banks and scales that evaluate symptoms, concerns, and issues that are relevant across disorders - along with measures that assess areas most relevant for specific patient populations.

The Neuro-QoL tool includes carefully developed and rigorously calibrated comprehensive item banks of patient-reported outcomes that are relevant to people with neurological disorders. The item banks include: Physical Health (e.g., Mobility; Fine Motor/ADL; Fatigue; Sleep Disturbance), Social Health (e.g., Ability to Participate in Social Roles & Activities; Satisfaction with Social Roles & Activities), Emotional Health (e.g., Depression, Anxiety, Stigma, Positive Affect & Well-Being; Emotional-Behavioral Dyscontrol), Cognitive Health (ie, Cognitive Function; Communication).

Item pools for the Neuro-QoL measurement system were developed through a process of engaging patients and other stakeholders (e.g., medical providers) to identify possible domains and items of interest/importance through focus groups, individual interviews and survey research. Existing items were identified, evaluated, and revised from existing items from the published literature. New items were written to fill identified construct gaps. Items were classified into domain-specific bins for conceptual and organizational purposes. Items were reviewed and revised using patient perspectives (e.g., cognitive interviews) and stakeholder judgment (expert item review) to assure understanding, relevance, and clarity. The process also included comprehensive

cultural/linguistic review of items to ensure ease of translatability, universality of concepts and clarity of phrasing, and multi-step comprehensive translation of items into Spanish language.

6.3 Secondary Measures - Neuropsychological Outcomes

Neuropsychological (NP) testing provides an opportunity to examine, with great sensitivity, potentially subtle but meaningful differences in outcomes between treatment groups.

We have selected measures that comprise the cognitive domain of the NIH Toolbox and are designed to leverage advantages unique to the NIH Toolbox tests including computerized administration (which allows precise and reliable timing), the availability of characterized composite scores, and the anticipation that the Toolbox cognitive battery will be commonly utilized in future neurological trials allowing for cross trial comparisons and aggregation of trial results.

Furthermore, this particular combination of tests has been carefully designed to be comprehensive, with special emphasis on measures of domains that have been found to be most significantly impacted in previous studies of cardiac arrest, namely learning, memory, attention and executive functioning. The NIH Toolbox tests can be subdivided into crystallized (i.e., general knowledge base) and fluid (i.e., thinking and reasoning) measures, providing information about both patients' premorbid and current functioning. A fluid composite score will be obtained for fluid measures (i.e., those expected to change with injury). A stability composite score will be calculated for crystallized measures (i.e., those not expected to change with injury). The use of two distinct composite scores rather than combining all into a single composite measure will result in both greater sensitivity of the fluid composite as well as provide us with a separate estimate of premorbid functioning.

Domain	Measure	Admin. Time (mins)
NIH Toolbox Tests		
Executive – Flexibility	Dimensional Change Card Sort Test	4
Executive – Inhibition	Flanker Inhibitory Control and Attention	3
Memory – Episodic	Picture Sequence Memory Test	7
Processing Speed	Pattern Comparison Processing Speed	3
Working Memory	List Sorting Working Memory Test	7
Language - Reading Decoding	Oral Reading Recognition Test	3

Language - Vocabulary Comprehension	Picture Vocabulary Test	4
Processing Speed - Working Memory	Oral symbol digit test (uses Toolbox App)	3
Memory – Verbal	Rey Auditory Verbal Learning Test	4

Neuropsychological testing has been limited to 45 minutes to enhance patient compliance and minimize patient fatigue. Patients who cannot tolerate the complete battery of tests and interviews in one session may be scheduled for a second session. Study participants will be evaluated at 3 and 12 months following OHCA. Study team members responsible for neuropsychological outcome assessment will be trained and certified per POST-ICECAP study procedures.

6.3.1 Brief Test of Adult Cognition by Telephone (BTACT) encompasses a wide range of cognitive domains and ability levels based on well-established, traditional neuropsychological tests.[138,139] The BTACT is a brief (10-15 minutes), telephone-based test available in English and Spanish, with good psychometric properties[140], and robust normative sample that includes adults and older adults with and without cognitive decline.[141] These advantages led to the inclusion of the BTACT in the NIH Common Data Elements for traumatic brain injury.[142]

Study participants will be evaluated at all five visits following OHCA.

6.3.2 The Disability Rating Scale (DRS) measures and tracks recovery in all three WHO-ICF categories: impairment, disability, and handicap for patients with DoC.[143,144] The DRS includes measures of eye-opening, verbalization, and motor response (derived from the Glasgow Coma Scale); cognitive understanding of feeding, dressing, and grooming; degree of assistance and supervision required; and employability. Scores range from 0 (no disability) to 29 (extreme vegetative state). DRS has in-person or telephone administration,[145] and has good test-retest, interrater reliability,[146] and concurrent and predictive validity.[143,147] We will score DRS from a structured interview with the participant's primary caregiver. Study participants with DoC will be evaluated at all five visits following OHCA.

6.4 Key Predictors and Modifiers of Outcome

6.4.1 Disposition and Rehabilitation details (Primary predictor; Aim 2). Study teams at each site will utilize medical records to document evaluations performed and recommendations made before hospital discharge by a physical, occupational, speech therapist, and physiatrist. We will categorize discharge disposition into 1) Home, 2) inpatient acute or subacute rehabilitation, 3) Assisted Living Facility, 4) skilled nursing facility, 5) Long term acute care, or 6) hospice. For patients who receive any form of rehabilitation within 1 month of discharge, we will collect the duration, frequency, type, and the total number of therapy sessions attended.

6.4.2 Self-reported race and ethnicity (Primary predictor, Aim 3) is the current gold standard and superior to measures derived from other sources.[148,149] Participants will be asked by the POST-ICECAP team to identify their ethnicity and then asked to identify their race on categories defined by NIH and US Census Bureau.

6.4.3 Psychological distress**.** *1: PTSD symptoms.* The PTSD Checklist (PCL-5)[150] is an extensively validated, 20-item scale developed by the National Center for PTSD that corresponds to *DSM-5* criteria for PTSD and will be keyed to the OHCA. We will use the continuous score and the National Center for PTSD's recommended cut-off point of 36 to categorize participants as likely having PTSD.[151] The PCL-5 has been validated for telephone administration[152] and has performed well in our OHCA participants.[53] *2: Depression and 3: Generalized (non-cardiac) Anxiety Symptoms* are common after OHCA[23,56,153] and are modifiers of functional and cognitive outcomes.[55,56] We will use the validated Patient Health Questionnaire (PHQ-8) to measure depressive symptoms[154,155] and the GAD-2 to measure generalized anxiety.[156]

6.4.4 Social Factors. Biological sex of participants is collected by ICECAP. POST-ICECAP will collect information about gender identity, sexual-orientation, caregiver status and involvement in day-to-day care, social support, education, occupation and socio-economic status as determined by the NIH. We will collect participant (or caregiver) reports about perceived experiences of racism and discrimination. We will collect their 9-digit Zip Code to estimate unique neighborhood-level indicators of socio-economic status (Area Deprivation Index,[62] Social vulnerability index, and Historical Redlining[157]).

6.4.5. Healthcare Utilization. At each assessment, we will ask participants about interval emergency room visits, hospitalizations, medical procedures, or outpatient visits. We will confirm if there were any new medications started for neurological and psychiatric diagnoses at each visit.

7. POTENTIAL RISKS: The respondent burden has been shown to vary in intensity and degree, depending upon the risk level of the research, the procedures that the research entails, and the individual participant's condition, mental state, and support systems. Though this study poses minimal risk to participants as it does not involve any intervention and participants are only asked to complete questionnaires (paper, computer, and phone), we will make every effort to accommodate participants' barriers without compromising the rigor and reproducibility of the study objectives. The study measures have been aligned with the ICECAP trial to remove redundancies. We may discover during screening or during follow-up assessments that a participant has conditions that warrant immediate treatment; a member of the research team will be available to talk to them and discuss appropriate care. A sincere effort to understand our participants' perception of respondent burden—whether the burden is psychological, physical, and/or economical - will be made.

8. TRAINING

POST-ICECAP will use the training infrastructure of the ICECAP trial. We successfully use methods for remote training and monitoring during the COVID-19 pandemic. At all POST-ICECAP enrollment locations, the site principal investigator, study teams, treating physicians, inpatient nursing staff, and outcome assessment investigators will receive appropriate training prior to study initiation. Training decay will be minimized with scheduled recertification and/or refresher training of study and clinical staff. Personnel responsible for outcomes assessment will be recertified frequently to ensure inter-rater reliability.

Clinical principal investigators from the study leadership will evaluate each site prior to initiation to provide

and assess adequacy of training and organization. Investigator meetings will occur periodically to address any impediments to subject enrollment, and protocol violations of concern.

9. STATISTICAL CONSIDERATIONS

9.1 Statistical Analysis Plan: Plan for ensuring transparency and unbiased reporting

Confidence and rigor in research are threatened[169] when there is selective reporting, selective adjustment for covariates, or performance of multiple unreported tests, all of which result in non-reproducible findings rather than trustworthy/reproducible evidence. To avoid this threat, we intend to post our methods and analysis plan on the Open Science Framework.

9.1.1 Primary analyses will be performed on patients with mRS<5 (awake patients; anticipated n=750) at 1 month, but descriptive/exploratory analyses will be performed on those w/ 1-month mRS=5 (n=250) (DoC patients). We will analyze these two strata separately as patients with DoC will have qualitatively different recovery and systematically different exposures to modifiers like rehabilitation (ineligible for inpatient acute rehabilitation). Each Aim focuses on the change in function, cognition, and HRQoL from 3 to 12 months.

9.1.2 Primary Aim 1 analyses. Among patients with mRS<5 at 1 month, we will examine/report the crosstabulation of 3-month mRS with 12-month mRS and the scatterplots of 12- versus 3-month scores on NIH-Toolbox and Neuro-QoL. While we anticipate that the 3- and 12-month outcomes will be substantially correlated, one of the primary rationales for conducting POST-ICECAP is our belief that these correlations will fall far short of 1.00, due to substantial between-person variability in the change from 3 to 12 months in each outcome. To test the hypotheses that initial illness severity (total OHCA score primary predictor, PCAC secondary predictor), early coronary angiography, and duration of hypothermia are associated with change from 3 to 12 months in mRS (primary outcome), NIH-Toolbox and Neuro-QoL (secondary outcomes), we will perform separate repeated measures ANOVAs/ANCOVAs with Time (3 vs 12 months) as the within-person repeated factor, one predictor and the *a priori* covariates (including Black race and Hispanic/Latinx ethnicity) as between-person factors, and the Time*Predictor and Time*Covariate interaction terms. The significance of the Time*Predictor term will be based on a 2-tailed, α=0.05 F-test. In the primary analysis, mRS will be treated as a continuous variable, but we will conduct a sensitivity repeated measures ordinal regression analysis where mRS is treated as an ordinal variable. Also, the effect of duration of hypothermia will be modeled as a 2-df quadratic curve, by including a squared term in the analysis, because we anticipate that its relationship to the outcomes is likely to be U-shaped (or inverted U-shaped) with the optimal duration lying somewhere in the middle of the distribution. Of note, we prefer the repeated measures model approach over modeling the 12-month outcome and including the 3-month outcome as a covariate, because POST-ICECAP is an observational study, and this alternative approach, while having greater statistical power, is more prone to bias.[171]

In addition to the analysis of the duration of hypothermia described above, we will conduct an intention-to-treat analysis of its effect, with no covariates, in the subset of ICECAP participants for whom the duration of hypothermia was randomly assigned. Again, the relationship will be modeled as a quadratic curve.

9.1.3 Primary Aims 2 and 3 analyses. The same analytic approach will be used to address Aims 2 and 3, with the primary predictors being the receipt of inpatient acute rehabilitation (vs. outpatient rehabilitation/no rehabilitation/discharge to a skilled nursing facility; Aim 2) or race/ethnicity (non-Hispanic Black race, Hispanic/Latinx ethnicity vs non-Black/non-Hispanic patients [reference group]; Aim 3). Secondary analyses for Aim 2 will categorize patients into 4 groups –inpatient acute rehabilitation, outpatient rehabilitation, skilled nursing facility, and home without rehabilitation – in order to explore differences among the latter three groups. Aim 2 analyses will exclude those whose 1-month mRS=0 since these patients would not be eligible for inpatient acute rehabilitation. Secondary analyses for Aim 3 will estimate mediation models evaluating the extent to which the associations of race/ethnicity with change in outcomes might be mediated through perceived racial discrimination, individual-level SES, neighborhood-level SES, psychosocial risk, and resilience factors.

9.2 Statistical and clinical basis for the sample size calculation

In the primary sample (those with mRS<5 at discharge, anticipated n=750) we anticipate 10% attrition,[53] resulting in n=675 with both 3- and 12-month mRS. We note that with complete data for 2 repeated measures (Y_3 and Y_{12}), the power to detect an association between X and ΔY ($=Y_{12} -- Y_3$) equals the power to test the Time*Predictor interaction term in the planned repeated measures analyses described above. N=675 with complete data provides ≥80%/90% power to detect Pearson (or partial) correlations of 0.109/0.126 between a predictor and the change from 3 to 12 months in function, cognition, or HRQoL (Aim 1), adjusting for 8 covariates; with multiple imputations, the effective sample size will slightly exceed 675 making these estimates of power somewhat conservative.[174] Assuming 35-45% receive inpatient acute rehabilitation and the exclusion of up to 5% due to their having mRS=0 at 1 month (ineligible for the Aim 2 analysis), N=641 provides ≥80%/90% power to detect an effect size of d=0.24/0.27 for the t-test comparing the mean change in outcomes from 3 to 12 months of these patients versus those not receiving inpatient acute rehabilitation (Aim 2). For other outcomes (cognition and HRQoL), we anticipate an additional 10% missing data due to those with mRS≥5 at either 3 or 12 months not being able to provide data (leaving n=607 with both 3- and 12-month data), resulting in ≥80%/90% power to detect Pearson correlations of 0.115/0.133 or larger and d=0.25/0.29 or larger. For Aim 3, the anticipated race/ethnic distribution of 35% non-Hispanic Blacks, 10% Hispanic/Latinx, and 55% non-Hispanic non-Blacks will provide ≥80%/90% power to detect d=0.25/0.29 for the comparison of 3- to 12-month change in function between non-Hispanic Blacks vs non-Hispanic non-Blacks and d=0.26/0.30 for the change in cognition or HRQoL. Although underpowered to detect associations with Hispanic ethnicity, we believe it is important to examine these.

The above demonstrates that the proposed POST-ICECAP study is adequately powered to detect “relatively small” associations with 3- to 12-month changes in those with 1-month mRS<5. The analyses of the subgroup with mRS=5 at 1 month will be descriptive/exploratory; we will not perform/report significance tests but will report 95% confidence intervals for parameters of interest.

10. DATA MANAGEMENT

10.1 Data Management Overview

Data management will be handled by the DCC, which is housed in the Data Coordination Unit, of the Department of Public Health Sciences, College of Medicine, Medical University of South Carolina (MUSC). All activities will be conducted in coordination with the study PIs, the sites, and the CCC. The data validation procedure will be implemented in two stages. First, the automated data checks will flag items that fail a rule, and the rule violation message will appear on the data entry screen at the time of data entry. The study coordinator at a site will see these rule violations and will be requested to address it. His/her choices are to: (1) correct the entry immediately; (2) correct the entry at a later time; or (3) if the entered data are confirmed to be correct, dismiss the rule by checking that option provided by WebDCU™. Any changes made to the data will have a full audit trail. Secondly, for some checks that are more complicated, additional consistency checks will be run periodically after data entry occurs at the site. All data items that fail the programmed consistency checks will be queried via the data clarification request (DCR) process initiated by the DCC data managers.

In addition to the study database, the DCC will provide the site staff password protected access to a standard set of web-enabled tools, including subject visit calendar, subject accrual status, case report form completion status, and outstanding DCR status pertaining to their respective sites.

10.2 Data Acquisition and Central Study Database

The entire study will be conducted using an electronic data acquisition method where all clinical data on enrolled subjects will be data entered (single-keyed) by the site personnel into a web-based data management system, WebDCU™. In order to provide user-friendly and easy-to-navigate interfaces, the WebDCU™ data capture screens are designed based upon individual CRFs. Prior to study start, the system is validated to ensure the data entry screens mirror the CRFs and that the pre-programmed data rules appropriately detect incorrect data. The data will be managed after data entry via a data clarification request from the DCC.

The latest version of each CRF will be available as a PDF file within the study database for use as worksheets by study personnel. This process facilitates version control of these study related documents, particularly since documents may evolve over the course of the study. This user-friendly web-based database system, developed by the DCC, will be used for data entry, data validation, project progress monitoring, subject tracking, user customizable report generation and secure data transfer.

10.3 Core Trial Database

Although POST-ICECAP requires a separate database, given its inclusion of ICECAP participants and its screen failures, it will be seamless to link POST-ICECAP data with ICECAP data using the shared ICECAP subject ID or screen failure ID. The DCC programmers will maintain the core clinical database. The relational database is based on the study CRFs using Microsoft SQL Server. The study database is programmed with extensive consistency checks (e.g., data type, range and logic checks) to flag potential data entry errors, including missing required data, data out of pre-specified range, and data conflicts and differences within each CRF and across

different CRFs.

10.4 Reporting Module

The WebDCU™ system also has a real-time reporting component that allows authorized users to view protocol specific reports as data listings and in a summary format, overall and by site, at any time during the study via the password protected system. The reports are presented in a manner that protects the integrity of the study (e.g., blinded assessment). The DCC will provide authorized study personnel access to a standard set of web-enabled tools on the WebDCU™. These tools allow the authorized research personnel to receive regular updates on accrual status and CRF status of enrolled subjects. Examples of available reports include subject enrollment logs, basic subject demographics, CRF completion rate and number of data queries outstanding and resolved. Like all reports generated on the system, data reported are in real time.

10.5 Security, Privacy, and Confidentiality

The DCU employs several layers of data protection to ensure data security. The first part of security is physical protection of the hardware systems employed by the DCU. The facility housing the DCU hardware is protected 24/7 by multiple layers of security, including electronic building and facility access secured by magnetic locks, onsite-personnel, monitored and recorded closed-circuit television, person-traps, and mandatory identity logging of all outside visitors. By limiting access, ensuring only authorized personnel have access, and tracking all entry, we can ensure this risk is minimal.

The network and system security is ensured by implementing multiple layered firewalls and a network intrusion prevention system for identifying and blocking malicious network activity in real time. Vulnerability scans are also run daily to ensure server and network hardening and preventing known application and OS vulnerabilities. Antiviral, Trojan, and worm protection is achieved by using Microsoft Forefront, updated on a daily basis. All communication with the web server and client is encrypted via SSL to make certain network traffic 'sniffing' poses no threat.

10.5.1 Audit Trail Function for WebDCU™: To maintain electronic records in the database as adequate and accurate, WebDCU™ system tracks all changes made to any patient-related and dynamically managed electronic records. This audit-trail information is created with a computer generated time-stamp and the user name in chronological order, when the original data is modified or deleted.

10.5.2 Data Redundancy: The Volume Shadow Copy Service is enabled for all DCU file servers and web servers used in the storage of clinical trial related documents and website files in order to provide a quick recovery solution for lost data. This allows for "point-in-time" copies of all edited files to be maintained in a hidden file space on the server. The copies or "snapshots" of edited files are taken 3 times daily.

10.5.3 Backup (Disaster Recovery): The databases housed in the WebDCU™ are backed up in two steps. The Microsoft® SQL server maintenance plans are set up to initiate the internal data integrity checkup procedures and to produce off-line backup copies of the database prior to backup by the MUSC enterprise certified backup tool of choice. The MUSC backup tool then delivers the full data backup to all DCU servers. In the event of a

weather related emergency or other situations where the university implements emergency procedures, the DCU also begins emergency full backup of all servers and other procedures in accordance with the DCU's Emergency Operation SOP.

10.6 Quality Assurance / Site Monitoring

Upon entry of CRFs into the study database, quality control procedures will be applied at each stage of data handling in order to ensure compliance with GCP guidelines, integrity of the study data, and document processing system reliability. Both remote and site data and source document monitoring will be employed in a coordinated fashion. Coordination and reporting of monitoring findings, data queries, site visits, and other performance metrics are centrally consolidated within a monitoring module incorporated into WebDCU™. All sites will undergo source document monitoring by the study site monitors from the CCC. Site monitors will review source documents and case report form information, and perform multifaceted quality assurance and protocol compliance reviews.

Site Monitors will also be able to generate DCRs when discrepancies are found during source to database verification. The DCRs will be generated, communicated to the sites, and resolved on the secure study website.

The study monitoring plan will define a baseline rate of monitoring visits, and items such as informed consent documentation that will undergo 100% source document monitoring. Additional monitoring visits will be conducted using a data-driven risk-based sampling strategy. Site monitoring will include a combination of on-site and remote source document verification.

Monitoring findings are reported to the study leadership and will be used to identify and correct problems in data collection and protocol performance. Corrective action plans will be collaboratively formed and implemented with sites. Creation, implementation, tracking, and closure of corrective action plans are also performed with the online monitoring module.

11. HUMAN SUBJECTS

The protection of human subjects is paramount in this study and in everything SIREN does. Strict compliance with all applicable regulations is mandatory.

11.1 Institutional Review Board (IRB) Review and Informed Consent

In accordance with NIH guidance NOT-OD-16-094, the POST-ICECAP trial will utilize a single IRB. In conjunction with the ICECAP trial, the SIREN Emergency Research- Central IRB (ER-CIRB), Advarra will serve as the IRB of record for all sites. All SIREN sites agree to rely upon the ER-CIRB for SIREN trials as a condition of their grant awards and/or master agreements. CIRB approval for POST-ICECAP will be obtained for all participating enrollment sites.

The ER-CIRB will be responsible for the initial and scheduled continuing review of applications, modifications, review of SAE, unexpected problems, and other reportable occurrences, and review and approval of informed consent documents.

The ER-CIRB will be administered in close collaboration with the SIREN Clinical Coordinating Center (CCC). Interactions between the POST-ICECAP sites and the ER-CIRB occur primarily through the CCC Site Managers who already work closely with the sites on all aspects of trial management. CCC Managers in turn will work closely with the ER-CIRB Coordinator at Advarra.

Applications, informed consent documents, study team composition, certifications, site sign-off confirmations, adverse events, and other required information are collected in WebDCU™, the SIREN Clinical Trial Management System (CTMS), and the IRB Information Technology platform (IRB- IT). Data transfers between IRB- IT to WebDCU reduce duplicative document submissions. All study-specific IRB communications and documents, including initial and continuing scheduled approvals, stamped, applications, notifications, and queries will be maintained in WebDCU™ as per prior regulatory activities.

POST-ICECAP sites will be responsible for meeting regulatory obligations, such as overseeing the implementation of the approved protocol, training and certification of investigators, stamped consent forms, conflict of interest management plans, and reporting unanticipated problems and study progress to the CIRB.

11.2 Subject Confidentiality

Case report form data and other records that leave the site will be identified only by the Study Identification Number (SID) to maintain subject confidentiality. Any material records will be kept in a locked file cabinet. Electronic records will be appropriately secured using compliant safeguards. Clinical information will not be released without written permission of the subject, except as necessary for monitoring by IRB, the FDA, the NIH, the OHRP, the sponsor, or the sponsor's designee.

Return of results of the study to participants, and other study updates and thanks will be facilitated by a separate central database of contact information for participants. Contacts may opt out of this database at the end of a subject's participation or anytime afterward.

11.3 Study Modification/Discontinuation

The study may be modified or discontinued at any time by the IRB, the NIH, the sponsor, the OHRP, or other government agencies as part of their duties to ensure that research subjects are protected.

12. STUDY ORGANIZATION

Overall study organization including reporting relationships are per the established structures and standard operating procedures of the SIREN.

The SIREN Clinical Coordinating Center at the University of Michigan will provide overall project management for the study. Participating sites will be involved through an amendment to the ongoing master agreement

between the SIREN CCC and SIREN Hubs. Hubs are responsible for subcontracting with and organizing clinical spoke sites. The SIREN Data Coordinating Center will provide all data management functions.

Daily management of the trial will be facilitated by weekly meetings of an operations working group and as a standing scheduled agenda item in weekly meetings of the SIREN operations committee. Strategic decision-making will take place in an executive committee incorporating all participants in the trial leadership.

The SIREN human subject protection working group will review and advise on the informed consent processes in this potentially cognitively impaired population.

12.1 Organizational Structure of the Investigative Teams

12.1.1 The Steering Committee is charged with the overall conduct of the study. Dr. Agarwal will be responsible for chairing the Committee, which will include all investigators at CUIMC, Co-PI Callaway, Co-I Meurer, and Co-I Yeatts. Members of the Steering Committee will meet on a bimonthly basis. The Steering Committee will also be responsible for the final research dissemination of the study's findings.

12.1.2 The Project Advisory Subcommittee is charged with aiding Dr. Agarwal in the successful completion of the study. This subcommittee will be co-chaired by Dr. Agarwal and Dr. Callaway. Co-Is Edmondson, Meurer, and Geocadin will be additional members. This Subcommittee will meet in person every month for 12 months, and then every 3 months during the remainder of the study. The frequency of meetings will be reassessed periodically and increased if necessary. The agenda of the meetings will focus on addressing issues that arise during the study, with the overall goal of completing the study.

12.1.3 The Data Management and Analysis Subcommittee will be responsible for data management for all collected data, and the performance of all statistical analyses proposed in the study. Dr. Agarwal will co-chair this committee with Dr. Schwartz. Other key members of this group will include a CU data analyst and the data managers from the Data Coordinating Center at MUSC.

12.1.4 Social Determinants of Health and Access to Rehabilitation Subcommittee will be responsible for compiling and coding the individual and neighborhood level social determinants of health and determining biopsychosocial factors influencing access to acute inpatient rehabilitation. Dr. Taylor and Dr. Wagner will co-chair this committee and meet with Dr. Agarwal and Dr. Callaway every 3 months.

Overall Structure of the POST-ICECAP Study Team



13. PUBLICATION OF RESEARCH FINDINGS

Publication of the results of this trial will be governed by the standard operating procedures developed by the SIREN and trial leadership available at https://siren.network/nett-resources/standard-operating-procedures

All presentations, abstracts, and manuscripts will include attribution of funding to the NIH and will be made available for review by the sponsor and the NIH.

14. REFERENCES

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017;135:e146-e603.
2. Vellano K, Crouch MPH, Rajdev MBA, McNally MPH. Cardiac Arrest Registry to Enhance Survival (CARES) Report on the Public Health Burden of Out-of-Hospital Cardiac Arrest.
3. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation 2012;125:620-37.
4. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e190-e252.
5. Sawyer KN, Camp-Rogers TR, Kotini-Shah P, et al. Sudden Cardiac Arrest Survivorship: A Scientific Statement From the American Heart Association. Circulation 2020;141:e654-e85.
6. Perkins GD, Callaway CW, Haywood K, et al. Brain injury after cardiac arrest. Lancet 2021.
7. van Diepen S, Girotra S, Abella BS, et al. Multistate 5-Year Initiative to Improve Care for Out-of-Hospital Cardiac Arrest: Primary Results From the HeartRescue Project. J Am Heart Assoc 2017;6.
8. Bunch TJ, White RD, Gersh BJ, et al. Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation. N Engl J Med 2003;348:2626-33.
9. Fugate JE, Brinjikji W, Mandrekar JN, et al. Post-cardiac arrest mortality is declining: a study of the US National Inpatient Sample 2001 to 2009. Circulation 2012;126:546-50.
10. Myerburg RJ, Fenster J, Velez M, et al. Impact of community-wide police car deployment of automated external defibrillators on survival from out-of-hospital cardiac arrest. Circulation 2002;106:1058-64.
11. Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002;346:557-63.
12. Callaway CW, Coppler PJ, Faro J, et al. Association of Initial Illness Severity and Outcomes After Cardiac Arrest With Targeted Temperature Management at 36 degrees C or 33 degrees C. JAMA Netw Open 2020;3:e208215.
13. Cronberg T, Lilja G, Rundgren M, Friberg H, Widner H. Long-term neurological outcome after cardiac arrest and therapeutic hypothermia. Resuscitation 2009;80:1119-23.
14. Hypothermia after Cardiac Arrest Study G. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002;346:549-56.
15. Elmer J, Rittenberger JC, Coppler PJ, et al. Long-term survival benefit from treatment at a specialty center after cardiac arrest. Resuscitation 2016;108:48-53.
16. Sunde K, Pytte M, Jacobsen D, et al. Implementation of a standardised treatment protocol for post resuscitation care after out-of-hospital cardiac arrest. Resuscitation 2007;73:29-39.
17. Merchant RM, Topjian AA, Panchal AR, et al. Part 1: Executive Summary: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2020;142:S337-S57.
18. Nolan JP, Maconochie I, Soar J, et al. Executive Summary: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation 2020;142:S2-S27.
19. Agarwal S, Presciutti A, Roth W, et al. Determinants of Long-Term Neurological Recovery Patterns Relative to Hospital Discharge Among Cardiac Arrest Survivors. Crit Care Med 2018;46:e141-e50.
20. Agarwal S SE, Presciutti A, Roh D, Park S, Claassen J, Elkind MSV, Edmondson D. Cognitive, psychological, and functional limitations after sudden cardiac arrest among a racially and ethnically diverse United States population. American Heart Association, Resuscitation symposium. Philadelphia, US2019.

21. Nichol G, Guffey D, Stiell IG, et al. Post-discharge outcomes after resuscitation from out-of-hospital cardiac arrest: A ROC PRIMED substudy. Resuscitation 2015;93:74-81.
22. Raina KD, Rittenberger JC, Holm MB, Callaway CW. Functional Outcomes: One Year after a Cardiac Arrest. Biomed Res Int 2015;2015:283608.
23. Wachelder EM, Moulaert VRMP, van Heugten C, Verbunt JA, Bekkers SCAM, Wade DT. Life after survival: long-term daily functioning and quality of life after an out-of-hospital cardiac arrest. Resuscitation 2009;80:517-22.
24. Moulaert VRM, van Heugten CM, Gorgels TPM, Wade DT, Verbunt JA. Long-term Outcome After Survival of a Cardiac Arrest: A Prospective Longitudinal Cohort Study. Neurorehabil Neural Repair 2017;31:530-9.
25. Becker LB, Aufderheide TP, Geocadin RG, et al. Primary outcomes for resuscitation science studies: a consensus statement from the American Heart Association. Circulation 2011;124:2158-77.
26. Geocadin RG. Understanding and enhancing functional outcomes after cardiac arrest: the need for a multidisciplinary approach to refocus on the brain. Resuscitation 2009;80:153-4.
27. Geocadin RG, Callaway CW, Fink EL, et al. Standards for Studies of Neurological Prognostication in Comatose Survivors of Cardiac Arrest: A Scientific Statement From the American Heart Association. Circulation 2019;140:e517-e42.
28. Cronberg T, Greer DM, Lilja G, Moulaert V, Swindell P, Rossetti AO. Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation. The Lancet Neurology 2020;19:611-22.
29. Elmer J, Callaway CW. The Brain after Cardiac Arrest. Semin Neurol 2017;37:19-24.
30. Elmer J, Callaway CW. Illness severity may identify patients who will benefit from hypothermia. Resuscitation 2022;173:154-5.
31. Coppler PJ, Callaway CW, Guyette FX, Baldwin M, Elmer J. Early risk stratification after resuscitation from cardiac arrest. J Am Coll Emerg Physicians Open 2020;1:922-31.
32. Callaway CW. Targeted Temperature Management After Cardiac Arrest: Finding the Right Dose for Critical Care Interventions. JAMA 2017;318:334-6.
33. Ghoshal S, Yang V, Brodie D, et al. In-Hospital Survival and Neurological Recovery Among Patients Requiring Renal Replacement Therapy in Post-Cardiac Arrest Period. Kidney Int Rep 2019;4:674-8.
34. Agarwal S, Sobczak E, Presciutti A, et al. Tracheostomy use, long-term survival, and neurological outcomes among cardiac arrest survivors. Resuscitation 2018;129:e19-e20.
35. Agarwal S SE, Tincher IM, Abukhadra SL, Roh DJ, Park S, Claassen J, Edmondson D, Taylor J, Wagner AK, Callaway C. Acute Inpatient Rehabilitation and Social Determinants of Health are associated with a good 1-year functional recovery pattern after hospital discharge from cardiac arrest. Under Review 2022.
36. Agarwal S SE, Tincher IM, Abukhadra SL, Roh DJ, Park S, Claassen J, Edmondson D, Taylor J, Wagner AK, Palta P, Callaway C. Social determinants of health are independently associated with Cognitive recovery patterns at 12 months relative to hospital discharge from cardiac arrest. Under Review 2022.
37. Coppler PJ, Elmer J, Rittenberger JC, Callaway CW, Wallace DJ. Demographic, social, economic and geographic factors associated with long-term outcomes in a cohort of cardiac arrest survivors. Resuscitation 2018;128:31-6.
38. Patrick J Coppler JE, Jon C Rittenberger, Clifton W Callaway and David J Wallace. Long-Term Outcomes Disparities in Survivors of Cardiac Arrest. Circulation 2017;136:A20629 2018.
39. Faramand Z, Alrawashdeh M, Helman S, et al. Your neighborhood matters: A machine-learning approach to the geospatial and social determinants of health in 9-1-1 activated chest pain. Res Nurs Health 2022;45:230-9.
40. Geocadin RG. Moving Beyond One-Size-Fits-All Treatment for Patients After Cardiac Arrest. JAMA Netw Open 2020;3:e208809.

41. Sawyer KN, Callaway CW, Wagner AK. Life After Death: Surviving Cardiac Arrest—an Overview of Epidemiology, Best Acute Care Practices, and Considerations for Rehabilitation Care. Current Physical Medicine and Rehabilitation Reports 2017;5:30-9.
42. Callaway CW. Improving Measurement of Outcomes in Cardiac Arrest Trials. Pediatr Crit Care Med 2016;17:1190-1.
43. Daya MR, Schmicker RH, Zive DM, et al. Out-of-hospital cardiac arrest survival improving over time: Results from the Resuscitation Outcomes Consortium (ROC). Resuscitation 2015;91:108-15.
44. Callaway CW, Donnino MW, Fink EL, et al. Part 8: Post-Cardiac Arrest Care: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015;132:S465-82.
45. Perkins GD, Callaway CW, Haywood K, et al. Brain injury after cardiac arrest. Lancet 2021;398:1269-78.
46. Presciutti A, Newman MM, Sawyer KN, Agarwal S, Perman SM. Gaps in the Provision of Cognitive and Psychological Resources in Cardiac Arrest Survivors with Good Neurologic Recovery. Ther Hypothermia Temp Manag 2021.
47. Sawyer KN. Reintegration & recovery after surviving cardiac arrest: Learning from the VACAR registry. Resuscitation 2020;146:255-7.
48. Sabedra AR, Kristan J, Raina K, et al. Neurocognitive outcomes following successful resuscitation from cardiac arrest. Resuscitation 2015;90:67-72.
49. Secher N, Adelborg K, Szentkuti P, et al. Evaluation of Neurologic and Psychiatric Outcomes After Hospital Discharge Among Adult Survivors of Cardiac Arrest. JAMA Netw Open 2022;5:e2213546.
50. Agarwal S, Presciutti A, Verma J, et al. Women have worse cognitive, functional, and psychiatric outcomes at hospital discharge after cardiac arrest. Resuscitation 2018;125:12-5.
51. Presciutti A, Verma J, Pavol M, et al. Posttraumatic stress and depressive symptoms characterize cardiac arrest survivors' perceived recovery at hospital discharge. Gen Hosp Psychiatry 2018;53:108-13.
52. Presciutti A, Sobczak E, Sumner JA, et al. The impact of psychological distress on long-term recovery perceptions in survivors of cardiac arrest. J Crit Care 2019;50:227-33.
53. Agarwal S, Presciutti A, Cornelius T, et al. Cardiac arrest and the subsequent hospitalization induced Posttraumatic Stress is associated with 1-year Risk of Major adverse cardiovascular Events and All-cause Mortality Crit Care Med2019.
54. Bohm M, Lilja G, Finnbogadottir H, et al. Detailed analysis of health-related quality of life after out-of-hospital cardiac arrest. Resuscitation 2019;135:197-204.
55. Lilja G, Nielsen N, Friberg H, et al. Cognitive function in survivors of out-of-hospital cardiac arrest after target temperature management at 33 degrees C versus 36 degrees C. Circulation 2015;131:1340-9.
56. Lilja G, Nilsson G, Nielsen N, et al. Anxiety and depression among out-of-hospital cardiac arrest survivors. Resuscitation 2015;97:68-75.
57. Lilja G, Nielsen N, Bro-Jeppesen J, et al. Return to Work and Participation in Society After Out-of-Hospital Cardiac Arrest. Circ Cardiovasc Qual Outcomes 2018;11:e003566.
58. Haywood KL, Whitehead L, Perkins GD. An international, consensus-derived Core Outcome Set for Cardiac Arrest effectiveness trials: the COSCA initiative. Curr Opin Crit Care 2019;25:226-33.
59. Agarwal S SE, Presciutti A, Roh D, Park S, Claassen J, Elkind MSV, Edmondson D. Cognitive, psychological, and functional limitations after sudden cardiac arrest among a racially and ethnically diverse United States from cardipopulation. American Heart Association, Resuscitation symposium. Philadelphia, USCirculation. 2019;140:A17.
60. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-9.

61. Hu J, Kind AJH, Nerenz D. Area Deprivation Index Predicts Readmission Risk at an Urban Teaching Hospital. Am J Med Qual 2018;33:493-501.
62. Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. N Engl J Med 2018;378:2456-8.
63. Kind AJ, Jencks S, Brock J, et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study. Ann Intern Med 2014;161:765-74.
64. Kim HS, Park KN, Kim SH, et al. Prognostic value of OHCA, C-GRApH and CAHP scores with initial neurologic examinations to predict neurologic outcomes in cardiac arrest patients treated with targeted temperature management. PLoS ONE 2020;15:e0232227.
65. Skrifvars MB, Varghese B, Parr MJ. Survival and outcome prediction using the Apache III and the out-of-hospital cardiac arrest (OHCA) score in patients treated in the intensive care unit (ICU) following out-of-hospital, in-hospital or ICU cardiac arrest. Resuscitation 2012;83:728-33.
66. Cronberg T, Lilja G, Horn J, et al. Neurologic Function and Health-Related Quality of Life in Patients Following Targeted Temperature Management at 33 degrees C vs 36 degrees C After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA Neurol 2015;72:634-41.
67. Kim YJ, Ahn S, Sohn CH, et al. Long-term neurological outcomes in patients after out-of-hospital cardiac arrest. Resuscitation 2016;101:1-5.
68. Kearney J, Dyson K, Andrew E, Bernard S, Smith K. Factors associated with return to work among survivors of out-of-hospital cardiac arrest. Resuscitation 2020;146:203-12.
69. Smith K, Andrew E, Lijovic M, Nehme Z, Bernard S. Quality of life and functional outcomes 12 months after out-of-hospital cardiac arrest. Circulation 2015;131:174-81.
70. Patel N, Rao VA, Heilman-Espinoza ER, Lai R, Quesada RA, Flint AC. Simple and reliable determination of the modified rankin scale score in neurosurgical and neurological patients: the mRS-9Q. Neurosurgery 2012;71:971-5; discussion 5.
71. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
72. Wilson JT, Hareendran A, Hendry A, Potter J, Bone I, Muir KW. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke 2005;36:777-81.
73. Beesems SG, Wittebrood KM, de Haan RJ, Koster RW. Cognitive function and quality of life after successful resuscitation from cardiac arrest. Resuscitation 2014;85:1269-74.
74. Lim C, Verfaellie M, Schnyer D, Lafleche G, Alexander MP. Recovery, long-term cognitive outcome and quality of life following out-of-hospital cardiac arrest. J Rehabil Med 2014;46:691-7.
75. Orbo M, Aslaksen PM, Larsby K, Schafer C, Tande PM, Anke A. Alterations in cognitive outcome between 3 and 12 months in survivors of out-of-hospital cardiac arrest. Resuscitation 2016;105:92-9.
76. Steinbusch CVM, van Heugten CM, Rasquin SMC, Verbunt JA, Moulaert VRM. Cognitive impairments and subjective cognitive complaints after survival of cardiac arrest: A prospective longitudinal cohort study. Resuscitation 2017;120:132-7.
77. Blennow Nordstrom E, Lilja G. Assessment of neurocognitive function after cardiac arrest. Curr Opin Crit Care 2019;25:234-9.
78. Sawyer KN, Brown F, Christensen R, Damino C, Newman MM, Kurz MC. Surviving sudden cardiac arrest: A pilot qualitative survey study of survivors. Ther Hypothermia Temp Manag 2016;6:76-84.
79. Haydon G, van der Riet P, Inder K. A systematic review and meta-synthesis of the qualitative literature exploring the experiences and quality of life of survivors of a cardiac arrest. Eur J Cardiovasc Nurs 2017;16:475-83.
80. Matthews EA, Magid-Bernstein J, Presciutti A, et al. Categorization of survival and death after cardiac arrest. Resuscitation 2017;114:79-82.

81. Elmer J, Torres C, Aufderheide TP, et al. Association of early withdrawal of life-sustaining therapy for perceived neurological prognosis with mortality after cardiac arrest. Resuscitation 2016;102:127-35.
82. Giacino JT, Katz DI, Schiff ND, et al. Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. Neurology 2018;91:450-60.
83. Xiao A, Callaway CW, Coppler PJ, University of Pittsburgh Post-Cardiac Arrest S. Long-term outcomes of post-cardiac arrest patients with severe neurological and functional impairments at hospital discharge. Resuscitation 2022;174:93-101.
84. Cullen NK, Crescini C, Bayley MT. Rehabilitation outcomes after anoxic brain injury: a case-controlled comparison with traumatic brain injury. PM R 2009;1:1069-76.
85. Howell K, Grill E, Klein AM, Straube A, Bender A. Rehabilitation outcome of anoxic-ischaemic encephalopathy survivors with prolonged disorders of consciousness. Resuscitation 2013;84:1409-15.
86. Rossetti AO, Oddo M, Logroscino G, Kaplan PW. Prognostication after cardiac arrest and hypothermia: a prospective study. Ann Neurol 2010;67:301-7.
87. Callaway CW. Implications of Cardiac Arrest and Resuscitation for Critical Care Medicine. Crit Care Clin 2020;36:xix-xx.
88. Elmer J, Coppler PJ, May TL, et al. Unsupervised learning of early post-arrest brain injury phenotypes. Resuscitation 2020;153:154-60.
89. Kim J, Kim K, Callaway CW, et al. Dynamic prediction of patient outcomes during ongoing cardiopulmonary resuscitation. Resuscitation 2017;111:127-33.
90. Coppler PJ, Elmer J, Calderon L, et al. Validation of the Pittsburgh Cardiac Arrest Category illness severity score. Resuscitation 2015;89:86-92.
91. Nassal MMJ, Nichols D, Demasi S, et al. External validation of Pittsburgh Cardiac Arrest Category illness severity score. Resuscitation 2022;172:32-7.
92. Weiss N, Venot M, Verdonk F, et al. Daily FOUR score assessment provides accurate prognosis of long-term outcome in out-of-hospital cardiac arrest. Rev Neurol (Paris) 2015;171:437-44.
93. Fugate JE, Rabinstein AA, Claassen DO, White RD, Wijdicks EF. The FOUR score predicts outcome in patients after cardiac arrest. Neurocrit Care 2010;13:205-10.
94. Iyer VN, Mandrekar JN, Danielson RD, Zubkov AY, Elmer JL, Wijdicks EF. Validity of the FOUR score coma scale in the medical intensive care unit. Mayo Clin Proc 2009;84:694-701.
95. Kate Flickinger PJC, McKenzie Brown and Jonathan Elmer. Trajectories of Sequential Organ Failure Assessment (sofa) Scores After Cardiac Arrest. Circulation 2020;142:A331 2020.
96. Cour M, Bresson D, Hernu R, Argaud L. SOFA score to assess the severity of the post-cardiac arrest syndrome. Resuscitation 2016;102:110-5.
97. Schenone AL, Cohen A, Patarroyo G, et al. Therapeutic hypothermia after cardiac arrest: A systematic review/meta-analysis exploring the impact of expanded criteria and targeted temperature. Resuscitation 2016;108:102-10.
98. Kirkegaard H, Soreide E, de Haas I, et al. Targeted Temperature Management for 48 vs 24 Hours and Neurologic Outcome After Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA 2017;318:341-50.
99. Yenari MA, Han HS. Neuroprotective mechanisms of hypothermia in brain ischaemia. Nat Rev Neurosci 2012;13:267-78.
100. Che D, Li L, Kopil CM, Liu Z, Guo W, Neumar RW. Impact of therapeutic hypothermia onset and duration on survival, neurologic function, and neurodegeneration after cardiac arrest. Crit Care Med 2011;39:1423-30.
101. Suh GJ, Kwon WY, Kim KS, et al. Prolonged therapeutic hypothermia is more effective in attenuating brain apoptosis in a Swine cardiac arrest model. Crit Care Med 2014;42:e132-42.

102. Skrifvars MB, Aneman A, Ameloot K. Individualized blood pressure targets during postcardiac arrest intensive care. Curr Opin Crit Care 2020;26:259-66.
103. Robba C, Badenes, R., Battaglini, D. et al. . Ventilatory settings in the initial 72 h and their association with outcome in out-of-hospital cardiac arrest patients: a preplanned secondary analysis of the targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest (TTM2) trial. Intensive Care Med (2022) 2022.
104. May TL, Riker RR, Fraser GL, et al. Variation in Sedation and Neuromuscular Blockade Regimens on Outcome After Cardiac Arrest. Crit Care Med 2018;46:e975-e80.
105. Reynolds JC, Callaway CW, El Khoudary SR, Moore CG, Alvarez RJ, Rittenberger JC. Coronary angiography predicts improved outcome following cardiac arrest: propensity-adjusted analysis. J Intensive Care Med 2009;24:179-86.
106. Harhash AA, May T, Hsu CH, et al. Incidence of cardiac interventions and associated cardiac arrest outcomes in patients with nonshockable initial rhythms and no ST elevation post resuscitation. Resuscitation 2021;167:188-97.
107. Yang MC, Meng-Jun W, Xiao-Yan X, Peng KL, Peng YG, Wang RR. Coronary angiography or not after cardiac arrest without ST segment elevation: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22197.
108. Camuglia AC, Randhawa VK, Lavi S, Walters DL. Cardiac catheterization is associated with superior outcomes for survivors of out of hospital cardiac arrest: review and meta-analysis. Resuscitation 2014;85:1533-40.
109. Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3:200-7.
110. Rittenberger JC, Raina K, Holm MB, Kim YJ, Callaway CW. Association between Cerebral Performance Category, Modified Rankin Scale, and discharge disposition after cardiac arrest. Resuscitation 2011;82:1036-40.
111. Joshi VL, Christensen J, Lejsgaard E, Taylor RS, Zwisler AD, Tang LH. Effectiveness of rehabilitation interventions on the secondary consequences of surviving a cardiac arrest: a systematic review and meta-analysis. BMJ Open 2021;11:e047251.
112. Jeanselme V, De-Arteaga M, Elmer J, Perman SM, Dubrawski A. Sex differences in post cardiac arrest discharge locations. Resusc Plus 2021;8:100185.
113. Raul A Garcia JAS, Saket Girotra, Bryan F McNally, Khadijah Breathett, Marina Del Rios, Kevin F Kennedy, Brahmajee K Nallamothu, Comilla Sasson, Paul S Chan and CARES Surveillance Group. Racial And Ethnic Differences In Bystander Cardiopulmonary Resuscitation For Witnessed Out-of-Hospital Cardiac Arrest. Circulation: Cardiovascular Quality and Outcomes 2022;15:A22 2022.
114. Reinier K, Sargsyan A, Chugh HS, et al. Evaluation of Sudden Cardiac Arrest by Race/Ethnicity Among Residents of Ventura County, California, 2015-2020. JAMA Netw Open 2021;4:e2118537.
115. Morris NA, Mazzeffi M, McArdle P, et al. Hispanic/Latino-Serving Hospitals Provide Less Targeted Temperature Management Following Out-of-Hospital Cardiac Arrest. J Am Heart Assoc 2021;10:e017773.
116. Bosson N, Fang A, Kaji AH, et al. Racial and ethnic differences in outcomes after out-of-hospital cardiac arrest: Hispanics and Blacks may fare worse than non-Hispanic Whites. Resuscitation 2019;137:29-34.
117. Jacobs CS, Beers L, Park S, et al. Racial and Ethnic Disparities in Postcardiac Arrest Targeted Temperature Management Outcomes. Crit Care Med 2020;48:56-63.
118. Moon S, Bobrow BJ, Vadeboncoeur TF, et al. Disparities in bystander CPR provision and survival from out-of-hospital cardiac arrest according to neighborhood ethnicity. Am J Emerg Med 2014;32:1041-5.
119. Khan MZ, Khan MU, Patel K, et al. Trends, Predictors and Outcomes After Utilization of Targeted Temperature Management in Cardiac Arrest Patients With Anoxic Brain Injury. Am J Med Sci 2020;360:363-71.

120. Starks MA, Schmicker RH, Peterson ED, et al. Association of Neighborhood Demographics With Out-of-Hospital Cardiac Arrest Treatment and Outcomes: Where You Live May Matter. JAMA Cardiol 2017;2:1110-8.
121. Casey SD, Mumma BE. Sex, race, and insurance status differences in hospital treatment and outcomes following out-of-hospital cardiac arrest. Resuscitation 2018;126:125-9.
122. Lupton JR, Schmicker RH, Aufderheide TP, et al. Racial disparities in out-of-hospital cardiac arrest interventions and survival in the Pragmatic Airway Resuscitation Trial. Resuscitation 2020;155:152-8.
123. George A. Mensah VF. Race, Ethnicity, and Cardiovascular Disease. JACC; V O L 7 8 , NO 2 4 , 2 0 2 1 2022.
124. Needham DM, Davidson J, Cohen H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med 2012;40:502-9.
125. Soto GJ, Martin GS, Gong MN. Healthcare disparities in critical illness. Crit Care Med 2013;41:2784-93.
126. Havranek EP, Mujahid MS, Barr DA, et al. Social Determinants of Risk and Outcomes for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2015;132:873-98.
127. Gary KW, Arango-Lasprilla JC, Stevens LF. Do racial/ethnic differences exist in post-injury outcomes after TBI? A comprehensive review of the literature. Brain Inj 2009;23:775-89.
128. Javed Z, Haisum Maqsood M, Yahya T, et al. Race, Racism, and Cardiovascular Health: Applying a Social Determinants of Health Framework to Racial/Ethnic Disparities in Cardiovascular Disease. Circ Cardiovasc Qual Outcomes 2022;15:e007917.
129. Stecker EC, Reinier K, Marijon E, et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol 2014;7:212-7.
130. Presciutti A, Shaffer J, Sumner JA, et al. Hyperarousal Symptoms in Survivors of Cardiac Arrest Are Associated With 13 Month Risk of Major Adverse Cardiovascular Events and All-Cause Mortality. Ann Behav Med 2020;54:413-22.
131. Gander ML, von Kanel R. Myocardial infarction and post-traumatic stress disorder: frequency, outcome, and atherosclerotic mechanisms. Eur J Cardiovasc Prev Rehabil 2006;13:165-72.
132. Copland C, Joekes K, Ayers S. Anxiety and post-traumatic stress disorder in cardiac patients. British Journal of Wellbeing 2011;2:21-5.
133. Edmondson D, Falzon L, Sundquist KJ, et al. A systematic review of the inclusion of mechanisms of action in NIH-funded intervention trials to improve medication adherence. Behaviour research and therapy 2017.
134. Kronish IM, Cornelius T, Schwartz JE, et al. Posttraumatic Stress Disorder and Electronically Measured Medication Adherence After Suspected Acute Coronary Syndromes. Circulation 2020;142:817-9.
135. Kronish IM, Edmondson D, Goldfinger JZ, Fei K, Horowitz CR. Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke 2012;43:2192-7.
136. Rosman L, Whited A, Lampert R, Mosesso VN, Lawless C, Sears SF. Cardiac anxiety after sudden cardiac arrest: Severity, predictors and clinical implications. Int J Cardiol 2015;181:73-6.
137. Hamang A, Eide GE, Rokne B, Nordin K, Øyen N. General anxiety, depression, and physical health in relation to symptoms of heart-focused anxiety- a cross sectional study among patients living with the risk of serious arrhythmias and sudden cardiac death. Health Qual Life Outcomes 2011;9:100.
138. Brim O, Ryff, C., and Kessler, R. The MIDUS national survey: an overview, in: How Healthy Are We? A National Study of Well-Being at Midlife. O Brim, C Ryff, R Kessler (eds) The University of Chicago Press: Chicago, IL, pps 1–36 2004.
139. Ryff C, and Lachman, M. Midlife in the United States (MIDUS 2): cognitive project, 2004–2006. Inter-university Consortium for Political and Social Research Ann Arbor, MI 2013;https://doi.org/10.3886/ICPSR25281.v5.

140. Dams-O'Connor K, Sy KTL, Landau A, et al. The Feasibility of Telephone-Administered Cognitive Testing in Individuals 1 and 2 Years after Inpatient Rehabilitation for Traumatic Brain Injury. J Neurotrauma 2018;35:1138-45.
141. Lachman ME, Agrigoroaei, S., Tun, P.A., and Weaver, S.L. Monitoring cognitive functioning: psychometric properties of the Brief Test of Adult Cognition by Telephone. Assessment 21, 404–417. 2014.
142. Stroke. NIoNDa. Common data elements: traumatic brain injury. wwwcommondataelementsnindsnihgov/TBIaspx#tab=Data_Standards 2012.
143. Bell KR, Temkin NR, Esselman PC, et al. The effect of a scheduled telephone intervention on outcome after moderate to severe traumatic brain injury: a randomized trial. Arch Phys Med Rehabil 2005;86:851-6.
144. Whyte J, Katz D, Long D, et al. Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: A multicenter study. Arch Phys Med Rehabil 2005;86:453-62.
145. Rappaport M. The Disability Rating and Coma/Near-Coma scales in evaluating severe head injury. Neuropsychol Rehabil 2005;15:442-53.
146. Rappaport M, Hall KM, Hopkins K, Belleza T, Cope DN. Disability rating scale for severe head trauma: coma to community. Arch Phys Med Rehabil 1982;63:118-23.
147. Whitlock JA, Jr. Functional outcome of low-level traumatically brain-injured admitted to an acute rehabilitation programme. Brain Inj 1992;6:447-59.
148. Mays VM, Ponce NA, Washington DL, Cochran SD. Classification of race and ethnicity: implications for public health. Annu Rev Public Health 2003;24:83-110.
149. Friedman DJ, Cohen BB, Averbach AR, Norton JM. Race/ethnicity and OMB Directive 15: implications for state public health practice. Am J Public Health 2000;90:1714-9.
150. Weathers FW, Litz BT, Herman DS. The PTSD Checklist (PCL): Reliability, validity, and diagnostic utility. annual convention of … 1993.
151. National Center for P. National Center for PTSD. January, 2014. Using the PTSD Checklist for DSM-IV (PCL). http://www.ptsd.va.gov/professional/pages/assessments/assessment-pdf/PCL-handout.pdf (accessed). 2014.
152. Guler E, Schmid J-P, Wiedemar L, Saner H, Schnyder U, von Känel R. Clinical diagnosis of posttraumatic stress disorder after myocardial infarction. Clin Cardiol 2009;32:125-9.
153. Desai R, Singh S, Patel K, Fong HK, Kumar G, Sachdeva R. The prevalence of psychiatric disorders in sudden cardiac arrest survivors: A 5-year nationwide inpatient analysis. Resuscitation 2019;136:131-5.
154. Williams LS, Brizendine EJ, Plue L, et al. Performance of the PHQ-9 as a screening tool for depression after stroke. Stroke 2005;36:635-8.
155. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13.
156. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry 2016;39:24-31.
157. Meier H, and Bruce Mitchell. Tracing the Legacy of Redlining: A New Method for Tracking the Origins of Housing Segregation. Washington, DC: National Community Reinvestment Coalition, February 1, 2022 https://ncrcorg/redlining-score/ 2022.
158. Adrie C, Cariou A, Mourvillier B, et al. Predicting survival with good neurological recovery at hospital admission after successful resuscitation of out-of-hospital cardiac arrest: the OHCA score. European heart journal 2006;27:2840-5.
159. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51.

160. Schwarzer R, & Jerusalem, M. Generalized Self-Efficacy Scale. J Weinman, S Wright, & M Johnston, Measures in health psychology: A user's portfolio Causal and control beliefs (pp 35-37) Windsor, UK: NFER-NELSON 1995.
161. Reiss S, McNally RJ. Theoretical issues in behavior therapy. San Diego: Academic; 1985.
162. Sears SF, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol 1999;22:481-9.
163. Lynch EE, Lorraine Halinka Malcoe, Sarah E. Laurent, Jason Richardson, Bruce C. Mitchell, and Helen C.S. Meier. The Legacy of Structural Racism: Associations between Historic Redlining, Current Mortgage Lending, and Health. SSM - Population Health 14 (June 2021): 100793
164. Krieger N, Smith K, Naishadham D, Hartman C, Barbeau EM. Experiences of discrimination: validity and reliability of a self-report measure for population health research on racism and health. Soc Sci Med 2005;61:1576-96.
165. Berkman LF, Carney R. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. … Heart Journal 2000.
166. Berkman LF, Leo-Summers L. Emotional support and survival after myocardial infarction: a prospective, population-based study of the elderly. Annals of internal … 1992.
167. Amirkhan JH. A factor analytically derived measure of coping: The Coping Strategy Indicator. Journal of Personality and Social Psychology, 59(5), 1066-1074 1990.
168. Prather AA, Epel ES, Cohen BE, Neylan TC, Whooley MA. Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: findings from the Heart and Soul Study. J Psychiatr Res 2013;47:1228-35.
169. Nosek BA, Alter G, Banks GC, et al. SCIENTIFIC STANDARDS. Promoting an open research culture. Science 2015;348:1422-5.
170. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219-42.
171. Van Breukelen G. ANCOVA versus change from baseline had more power in randomized studies and more bias in nonrandomized studies. . Journal of Clinical Epidemiology 2006;59: 920–925 2006.
172. S H. A simple sequentially rejective multiple test procedure. . Scandinavian Journal of Statistics 6 (2): 65–70 1979.
173. Benjamini Y HY. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 57 (1): 289–300 1995.
174. T. G. The impact of multiple imputation on the Type II error rate of the t test. . Wayne State University Dissertations 1536 https://digitalcommonswayneedu/oa_dissertations/1536 2016.

PROTOCOL CHANGES

Page	Version 1	Version 2
	POST-ICECAP Protocol Version 1.0	POST-ICECAP Protocol Version 2.0
Signature Page	03/01/2024	16-May-2025
6	3. Determine whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such disparities.	3. Determine whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such differences.
6	1. NIH toolbox Age-corrected Standard Score for 3 and 12 months in-person visits; Brief Test of Adult Cognition by Telephone (BTACT) total score at 1-, 6-, and 9-month phone visits. 2. Patient-reported Health-Related Quality of Life as measured on NIH Neuro-QoL at 3 and 12 months in-person visits	1. NIH toolbox Age-corrected Standard Score for 3 and 12 months in-person visits; Brief Test of Adult Cognition by Telephone (BTACT) total score at 1-,3-, 6-, 9- and 12-month phone visits. 2. Patient-reported Health-Related Quality of Life as measured on NIH Neuro-QoL at 3 and 12 months in-person visits
7	Each Aim focuses on the change in function, cognition, and HRQoL from 3 to 12 months, i.e., the period beyond the ICECAP endpoint.	Each Aim focuses on the change in function, cognition, and HRQoL from 3 to 12 months.
8	We will enroll 1,000 patients who were screened for ICECAP and survived to 1 month. The parent ICECAP trial includes a telephone follow-up visit at 1 month and an in-person visit at 3 months. The ancillary study will add two telephone/videoconferencing visits at 6 and 9 months and an in-person visit at 12	We will enroll 1,000 patients who were treated with targeted temperature management (TTM) and survived to 1 month at multiple sites, many of whom are actively screening and enrolling in ICECAP. The ICECAP trial includes a telephone follow-up visit at 1 month and an in-person visit at 3 months. This overlapping study will add two telephone/videoconferencing visits at 6 and 9 months and an in-person visit at

	months after OHCA.	12 months after OHCA.
8	Finally, in Aim 3, we will test whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such disparities.	Finally, in Aim 3, we will test whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such differences.
9	Determine whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such disparities.	Determine whether non-Hispanic Black and Hispanic/Latinx patients have less favorable changes in recovery outcomes between 3 and 12 months and explore mechanisms for such differences.
11	Our study may also point to racial and/or ethnic disparities in recovery, as well as intervention targets to reduce such disparities.	Our study may also point to racial and/or ethnic differences in recovery, as well as intervention targets to reduce such differences.
14	POST-ICECAP will leverage the comprehensive and systematically collected physiological and biomedical data in the related ICECAP trial to examine how these physiological assessments are associated with recovery from 3-12 months.	POST-ICECAP will leverage the comprehensive and systematically collected physiological and biomedical data to examine how these physiological assessments are associated with recovery from 3-12 months.
15	While the ICECAP parent trial will examine associations between the duration of hypothermia and 3-month outcomes, POST-ICECAP will test whether the duration of hypothermia is associated with continued recovery from 3-12 months.	While the ICECAP trial will examine associations between the duration of hypothermia and 3-month outcomes, POST-ICECAP will test whether the duration of hypothermia is associated with continued recovery from 3-12 months.

15	There are significant sex-based disparities in receipt of inpatient acute rehabilitation.	There are significant sex-based differences in receipt of inpatient acute rehabilitation.
16	Prior research identified racial and ethnic disparities in OHCA incidence and mortality.[113-122] There is a gap in our knowledge about racial/ethnic disparities in longer-term recovery after OHCA. Understanding which SDOH contributes to racial and ethnic disparities after OHCA is critical for reducing those disparities.	Prior research identified racial and ethnic differences in OHCA incidence and mortality.[113-122] There is a gap in our knowledge about racial/ethnic differences in longer-term recovery after OHCA. Understanding which SDOH contributes to racial and ethnic differences after OHCA is critical for reducing those differences.
16	Limited data on other cardiac and critical care illnesses indicate that historically marginalized groups are at higher risk of poor functional outcomes with worse HRQoL, impaired societal participation, and perhaps because of inequality of follow-up care or employment security, compared with White patients.	Limited data on other cardiac and critical care illnesses indicate that historically marginalized groups are at higher risk of poor functional outcomes with worse HRQoL, impaired societal participation, and perhaps because of differences in follow-up care or employment security, compared with White patients.
16	The disparities we found are clearly multifactorial, with self-reported race aligning with other individual-, structural-, and hospital-level factors at several points in the course of recovery after OHCA. Structural racism and race-based stressors may also contribute to these disparities. POST-ICECAP will deepen our understanding of where disparities exist in OHCA recovery and may point to targets for interventions to reduce health disparities in OHCA.	The differences we found are clearly multifactorial, with self-reported race aligning with other individual-, structural-, and hospital-level factors at several points in the course of recovery after OHCA. Structural racism and race-based stressors may also contribute to these differences. POST-ICECAP will deepen our understanding of where differences exist in OHCA recovery and may point to targets for interventions to reduce health differences in OHCA.
18	Hub and spoke hospitals from the SIREN network who are participating in the ICECAP trial, will be eligible for participation in POST-ICECAP. Approximately 50 hospitals are anticipated to enroll an average of 5 subjects per year. The enrollment period is anticipated to be	Hub and spoke hospitals from the SIREN network who are using targeted temperature management, whether or not they are participating in ICECAP, will be eligible for participation in POST-ICECAP. At least 50 hospitals are anticipated to enroll an average of 5 subjects per year. The

	4 years (estimated accrual rate of 21 subjects per month).	enrollment period is anticipated to be 4 years (estimated accrual rate of 21 subjects per month).
18	Study population will comprise adults, enrolled in or screened for the ICECAP trial, who survived to 1 month after an OHCA. Detailed inclusion/exclusion criteria are listed in **Table 1**. POST-ICECAP will recruit from a racially and ethnically diverse population of OHCA survivors in the US that is often difficult to engage in research and is recognized by the NIH as requiring special efforts to ensure adequate representation in clinical studies. Enrolling a diverse cohort of OHCA survivors by using the geographically diverse SIREN/ICECAP sites is a major strength of our protocol.	Study population will comprise adults, treated with targeted temperature management, including those enrolled in or screened for the ICECAP trial, who survived to 1 month after an OHCA. Detailed inclusion/exclusion criteria are listed in **Table 1**. Enrolling a cohort of OHCA survivors by using the geographically widespread SIREN sites is a major strength of our protocol.
18	• Age ≥ 18 years • Coma after resuscitation from OHCA • Patients who were either screened or enrolled in the ICECAP trial • Received targeted temperature management • Participant survived to 1 month • Signed ICF by a patient or an authorized representative	• Age ≥ 18 years • Coma after resuscitation from OHCA • Received targeted temperature management • Participant survived to 1 month • Signed ICF by a patient or an authorized representative
19		At hospitals who are not enrolling in ICECAP, research teams will screen and approach patients using similar methods.
	To minimize participant burden, the data collection schedule differs for subjects enrolled in ICECAP and ICECAP screen failures. For subjects enrolled in ICECAP, POST-ICECAP will not repeat measures collected as part of the overlapping 1 and 3 month visit with the parent ICECAP trial. Specifically, POST-ICECAP will capture the	To minimize participant burden, the data collection schedule differs for ICECAP and non-ICECAP participants. For subjects enrolled in ICECAP, POST-ICECAP will not repeat measures collected as part of the overlapping 1 and 3 month visit with the ICECAP trial. Specifically, POST-ICECAP will capture the mRS at 1 and 3 months,

	mRS at 1 and 3 months, neuropsychological testing, and HRQoL assessments for ICECAP screen failures but not for subjects enrolled in ICECAP. Beyond 3 months post-arrest, the collection schedule is the same for both subjects enrolled in ICECAP and ICECAP screen failures.	neuropsychological testing, and HRQoL assessments for non-ICECAP participants but not for subjects enrolled in ICECAP. Beyond 3 months post-arrest, the collection schedule is the same for both ICECAP and non-ICECAP participants.
19	If unable to attend in-person visits at 3 or 12 months, we will substitute in-person neuropsychological testing with a telephone-based assessment.	
20	The ICECAP research teams have surveillance strategies in place to screen all OHCA patients at participating hospitals. Research teams track ICECAP randomized patients through 3 months and ICECAP screen failures through hospital discharge. The latter are included by design to measure the generalizability of the ICECAP randomized population. Thus, POST-ICECAP can use research teams that already have contact and entrée to approach all the OHCA patients admitted at their hospitals and do not need to create or directly support the screening process.	The ICECAP research teams have surveillance strategies in place to screen all OHCA patients at participating hospitals. Research teams track ICECAP randomized patients through 3 months and ICECAP screen failures through hospital discharge. Thus, POST-ICECAP can use research teams that already have contact and entrée to approach all the OHCA patients admitted at their hospitals and do not need to create or directly support the screening process. At hospitals who are not enrolling in ICECAP, research teams will screen and approach patients using similar methods.
20	Note: POST-ICECAP will still capture these measures for ICECAP screen failures.	Note: POST-ICECAP will still capture these measures for non-ICECAP participants.
22	Study team members responsible for neuropsychological outcome assessment will be trained and certified per ICECAP study procedures.	Study team members responsible for neuropsychological outcome assessment will be trained and certified per POST-ICECAP study procedures.
22		Study participants will be evaluated at all five visits following OHCA.

22		Study participants with DoC will be evaluated at all five visits following OHCA.
22	Disposition and Rehabilitation details (Primary predictor; Aim 2). Study teams at each site will utilize medical records to document evaluations performed before hospital discharge by a physical, occupational, speech therapist, and physiatrist and concordance between recommended and actual dispositions. We will categorize discharge disposition into 1) Home, 2) inpatient acute or subacute rehabilitation, 3) Assisted Living Facility, 4) skilled nursing facility, 5) Long term acute care, or 6) hospice. For patients who receive any form of rehabilitation within 1 month of discharge, we will collect the duration, frequency, and the total number of therapy sessions attended.	Disposition and Rehabilitation details (Primary predictor; Aim 2). Study teams at each site will utilize medical records to document evaluations performed and recommendations made before hospital discharge by a physical, occupational, speech therapist, and physiatrist. We will categorize discharge disposition into 1) Home, 2) inpatient acute or subacute rehabilitation, 3) Assisted Living Facility, 4) skilled nursing facility, 5) Long term acute care, or 6) hospice. For patients who receive any form of rehabilitation within 1 month of discharge, we will collect the duration, frequency, type, and the total number of therapy sessions attended.
24	POST-ICECAP will use the training infrastructure of the ICECAP trial. The Clinical Coordinating Center (CCC) will execute POST-ICECAP sub-contracts as amendments to the SIREN master contract and will train and monitor site performance. SIREN utilizes multiple methods to optimize the education and training of site personnel including face-to-face training at investigator meetings and online modules and certifications for re-training or training of new personnel. We successfully adapted all of these methods to remote training and monitoring during the COVID-19 pandemic.	POST-ICECAP will use the training infrastructure of the ICECAP trial. We successfully use methods for remote training and monitoring during the COVID-19 pandemic.
24	Each Aim focuses on the change in function, cognition, and HRQoL from 3 to 12 months; i.e., the period beyond the	Each Aim focuses on the change in function, cognition, and HRQoL from 3 to 12 months.

	ICECAP endpoint.	
27	Although POST-ICECAP requires a separate database, given its inclusion of ICECAP screen failures, it will be seamless to link POST-ICECAP data with ICECAP data using the shared ICECAP subject ID or screen failure ID.	Although POST-ICECAP requires a separate database, given its inclusion of ICECAP participants and its screen failures, it will be seamless to link POST-ICECAP data with ICECAP data using the shared ICECAP subject ID or screen failure ID.
27	The study database is programmed with extensive consistency checks (e.g., data type, range and logic checks) to flag potential data entry errors, including missing required data, data out of pre-specified range, and data conflicts and disparities within each CRF and across different CRFs.	The study database is programmed with extensive consistency checks (e.g., data type, range and logic checks) to flag potential data entry errors, including missing required data, data out of pre-specified range, and data conflicts and differences within each CRF and across different CRFs.
30	The SIREN human subject protection working group will review and advise on the informed consent processes in this potentially vulnerable population.	The SIREN human subject protection working group will review and advise on the informed consent processes in this potentially cognitively impaired population.